1
|
Adachi M, Motegi S, Nagahara K, Ochi A, Toyoda J, Mizuno K. Classification of pseudohypoaldosteronism type II as type IV renal tubular acidosis: results of a literature review. Endocr J 2023. [PMID: 37081692 DOI: 10.1507/endocrj.ej22-0607] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/22/2023] Open
Abstract
Pseudohypoaldosteronism (PHA) type II (PHA2) is a genetic disorder that leads to volume overload and hyperkalemic metabolic acidosis. PHA2 and PHA type I (PHA1) have been considered to be genetic and pediatric counterparts to type IV renal tubular acidosis (RTA). Type IV RTA is frequently found in adults with chronic kidney disease and is characterized by hyperchloremic hyperkalemic acidosis with normal anion gap (AG). However, we recently observed that PHA1 was not always identical to type IV RTA. In this study, we focused on the aid-base balance in PHA2. Through a literature search published between 2008-2020, 46 molecularly diagnosed cases with PHA2 were identified (median age of 14 years). They comprised 11 sets of familial and 16 sporadic cases and the pathology was associated with mutations in WNK 4 (n = 1), KLHL3 (n = 17), and CUL3 (n = 9). The mean potassium (K+) level was 6.2 ± 0.9 mEq/L (n = 46, range 4.0-8.6 mEq/L), whereas that of chloride (Cl-) was 110 ± 3.5 mEq/L (n = 41, 100-119 mEq/L), with 28 of 41 cases identified as hyperchloremic. More than half of the cases (18/35) presented with metabolic acidosis. Although AG data was obtained only in 16 cases, all but one cases were within normal AG range. Both Cl- and HCO3- levels showed significant correlations with K+ levels, which suggested that the degree of hyperchloremia and acidosis reflect the clinical severity, and is closely related to the fundamental pathophysiology of PHA2. In conclusion, our study confirmed that PHA2 is compatible with type IV RTA based on laboratory findings.
Collapse
Affiliation(s)
- Masanori Adachi
- Department of Pediatrics, Showa University School of Medicine, Tokyo 142-8555, Japan
| | - Sakura Motegi
- Department of Pediatrics, Showa University School of Medicine, Tokyo 142-8555, Japan
| | - Keiko Nagahara
- Department of Pediatrics, Showa University School of Medicine, Tokyo 142-8555, Japan
| | - Ayako Ochi
- Department of Pediatrics, Showa University School of Medicine, Tokyo 142-8555, Japan
| | - Junya Toyoda
- Department of Pediatrics, Showa University School of Medicine, Tokyo 142-8555, Japan
| | - Katsumi Mizuno
- Department of Pediatrics, Showa University School of Medicine, Tokyo 142-8555, Japan
| |
Collapse
|
2
|
Cecchi M, Adachi M, Basile A, Buhl DL, Chadchankar H, Christensen S, Christian E, Doherty J, Fadem KC, Farley B, Forman MS, Honda S, Johannesen J, Kinon BJ, Klamer D, Marino MJ, Missling C, O'Donnell P, Piser T, Puryear CB, Quirk MC, Rotte M, Sanchez C, Smith DG, Uslaner JM, Javitt DC, Keefe RSE, Mathalon D, Potter WZ, Walling DP, Ereshefsky L. Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers. Schizophr Res 2023; 254:178-189. [PMID: 36921403 DOI: 10.1016/j.schres.2023.02.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2022] [Revised: 11/23/2022] [Accepted: 02/10/2023] [Indexed: 03/18/2023]
Abstract
OBJECTIVE Complexity and lack of standardization have mostly limited the use of event-related potentials (ERPs) and quantitative EEG (QEEG) biomarkers in drug development to small early phase trials. We present results from a clinical study on healthy volunteers (HV) and patients with schizophrenia (SZ) that assessed test-retest, group differences, variance, and correlation with functional assessments for ERP and QEEG measures collected at clinical and commercial trial sites with standardized instrumentation and methods, and analyzed through an automated data analysis pipeline. METHODS 81 HV and 80 SZ were tested at one of four study sites. Subjects were administered two ERP/EEG testing sessions on separate visits. Sessions included a mismatch negativity paradigm, a 40 Hz auditory steady-state response paradigm, an eyes-closed resting state EEG, and an active auditory oddball paradigm. SZ subjects were also tested on the Brief Assessment of Cognition (BAC), Positive and Negative Syndrome Scale (PANSS), and Virtual Reality Functional Capacity Assessment Tool (VRFCAT). RESULTS Standardized ERP/EEG instrumentation and methods ensured few test failures. The automated data analysis pipeline allowed for near real-time analysis with no human intervention. Test-retest reliability was fair-to-excellent for most of the outcome measures. SZ subjects showed significant deficits in ERP and QEEG measures consistent with published academic literature. A subset of ERP and QEEG measures correlated with functional assessments administered to the SZ subjects. CONCLUSIONS With standardized instrumentation and methods, complex ERP/EEG testing sessions can be reliably performed at clinical and commercial trial sites to produce high-quality data in near real-time.
Collapse
Affiliation(s)
| | | | - A Basile
- Merck & Co., Inc., Kenilworth, NJ, USA
| | | | | | | | | | | | | | | | | | | | | | | | - D Klamer
- Anavex Life Sciences Corp., NY, USA
| | | | | | | | - T Piser
- Onsero Therapeutics, MA, USA
| | | | | | | | | | | | | | | | | | - D Mathalon
- University of California, San Francisco, CA, USA
| | - W Z Potter
- Independent Consultant, Philadelphia, PA, USA
| | | | - L Ereshefsky
- CenExel Research, USA; University of Texas Health Science Center at San Antonio, TX, USA
| |
Collapse
|
3
|
Toyoda J, Adachi M, Ochi A, Okada Y, Honda A, Mizuno K, Nozu K. Pseudo-Bartter syndrome in an infant without obvious underlying conditions: a case report. Clin Pediatr Endocrinol 2023. [DOI: 10.1297/cpe.2022-0069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/20/2023] Open
Affiliation(s)
- Junya Toyoda
- Department of Pediatrics, Showa University School of Medicine, Tokyo, Japan
| | - Masanori Adachi
- Department of Pediatrics, Showa University School of Medicine, Tokyo, Japan
| | - Ayako Ochi
- Department of Pediatrics, Showa University School of Medicine, Tokyo, Japan
| | - Yuki Okada
- Department of Pediatrics, Showa University School of Medicine, Tokyo, Japan
| | - Aiko Honda
- Department of Pediatrics, Showa University School of Medicine, Tokyo, Japan
| | - Katsumi Mizuno
- Department of Pediatrics, Showa University School of Medicine, Tokyo, Japan
| | - Kandai Nozu
- Department of Pediatrics, Kobe University Graduate School of Medicine, Hyogo, Japan
| |
Collapse
|
4
|
Adachi M, Nagahara K, Ochi A, Toyoda J, Muroya K, Mizuno K. Acid-base imbalance in pseudohypoaldosteronism type 1 in comparison with type IV renal tubular acidosis. J Endocr Soc 2022; 6:bvac147. [PMID: 36320629 PMCID: PMC9597475 DOI: 10.1210/jendso/bvac147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/02/2022] [Indexed: 11/26/2022] Open
Abstract
Context Pseudohypoaldosteronism type 1 (PHA1) has been treated as a genetic variant of type IV renal tubular acidosis (RTA), leading to the conception that PHA1 develops hyperchloremic acidosis with a normal anion gap (AG). Objective To delineate the acid–base imbalance in PHA1A (dominant type) and PHA1B (recessive type). Methods We conducted the following: (1) a retrospective chart review of our patient with PHA1B, and (2) a literature search of PHA1 cases focusing on acid–base balance. The main outcome measures were the incidence and nature of acidosis, including chloride levels and AG. Results In our patient with PHA1B, 7 salt-wasting episodes were analyzed. Acidosis was ascertained each time, and it was accompanied by hypochloremia except in 1 episode. AG was elevated in 5 episodes, while hyperlacticaemia was present in 3. In the literature, 41 cases of PHA1A and 65 cases of PHA1B have been identified. During salt-wasting crises, acidosis developed in 85% of PHA1A cases and 87% of PHA1B cases. Hypochloremia was present in 69% of PHA1A cases with available data (n = 13) and 54% of eligible PHA1B cases (n = 13), with mean chloride levels of 96 mEq/L and 95 mEq/L, respectively. Increased AG was less frequently reported (14% in PHA1A and 44% in PHA1B). Conclusions Patients with PHA1 frequently presented with metabolic acidosis. However, hyperchloremia may not be a universal finding, whereas hypochloremia and increased AG may occur in a substantial proportion of the patients.
Collapse
Affiliation(s)
- Masanori Adachi
- Department of Pediatrics, Showa University School of Medicine , Tokyo, 142-8555 , JAPAN
| | - Keiko Nagahara
- Department of Pediatrics, Showa University School of Medicine , Tokyo, 142-8555 , JAPAN
| | - Ayako Ochi
- Department of Pediatrics, Showa University School of Medicine , Tokyo, 142-8555 , JAPAN
| | - Junya Toyoda
- Department of Pediatrics, Showa University School of Medicine , Tokyo, 142-8555 , JAPAN
| | - Koji Muroya
- Department of Endocrinology and Metabolism, Kanagawa Children’s Medical Center , Yokohama 232-8555 , JAPAN
| | - Katsumi Mizuno
- Department of Pediatrics, Showa University School of Medicine , Tokyo, 142-8555 , JAPAN
| |
Collapse
|
5
|
Narumi S, Opitz R, Nagasaki K, Muroya K, Asakura Y, Adachi M, Abe K, Sugisawa C, Kühnen P, Ishii T, Nöthen MM, Krude H, Hasegawa T. GWAS of thyroid dysgenesis identifies a risk locus at 2q33.3 linked to regulation of Wnt signaling. Hum Mol Genet 2022; 31:3967-3974. [PMID: 35535691 DOI: 10.1093/hmg/ddac093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Revised: 03/27/2022] [Accepted: 04/19/2022] [Indexed: 11/12/2022] Open
Abstract
Congenital hypothyroidism due to thyroid dysgenesis (TD), presented as thyroid aplasia, hypoplasia or ectopia, is one of the most prevalent rare diseases with an isolated organ malformation. The pathogenesis of TD is largely unknown, although a genetic predisposition has been suggested. We performed a genome-wide association study (GWAS) with 142 Japanese TD cases and 8380 controls, and found a significant locus at 2q33.3 (top SNP, rs9789446: P = 4.4 × 10-12), which was replicated in a German patient cohort (P = 0.0056). A subgroup analysis showed that rs9789446 confers a risk for thyroid aplasia (per allele odds ratio = 3.17) and ectopia (3.12) but not for hypoplasia. Comprehensive epigenomic characterization of the 72-kb disease-associated region revealed that it was enriched for active enhancer signatures in human thyroid. Analysis of chromosome conformation capture data showed long-range chromatin interactions of this region with promoters of two genes, FZD5 and CCNYL, mediating Wnt signaling. Moreover, the finding that rs9789446 is a thyroid-specific expression quantitative trait loci, adding further evidence for a cis-regulatory function of this region in thyroid tissue. Specifically, because the risk rs9789446 allele is associated with increased thyroidal expression of FDZ5 and CCNYL1 and given the recent demonstration of perturbed early thyroid development following over-activation of Wnt signaling in zebrafish embryos, an enhanced Wnt signaling in risk allele carriers provide a biologically plausible TD mechanism. In conclusion, our work found the first risk locus for TD, exemplifying that in rare diseases with relatively low biological complexity, GWAS may provide mechanistic insights even with a small sample size.
Collapse
Affiliation(s)
- Satoshi Narumi
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan.,Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
| | - Robert Opitz
- Institute for Experimental Pediatric Endocrinology, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin und Humboldt-Universität zu Berlin, Berlin, Germany
| | - Keisuke Nagasaki
- Division of Pediatrics, Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Koji Muroya
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Yumi Asakura
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Kiyomi Abe
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
| | - Chiho Sugisawa
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
| | - Peter Kühnen
- Institute for Experimental Pediatric Endocrinology, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin und Humboldt-Universität zu Berlin, Berlin, Germany
| | - Tomohiro Ishii
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
| | - Markus M Nöthen
- Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany
| | - Heiko Krude
- Institute for Experimental Pediatric Endocrinology, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin und Humboldt-Universität zu Berlin, Berlin, Germany
| | - Tomonobu Hasegawa
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
6
|
Tanase-Nakao K, Muroya K, Adachi M, Abe K, Hasegawa T, Narumi S. A patient with congenital hypothyroidism due to a <i>PAX8</i> frameshift variant accompanying a urogenital malformation. Clin Pediatr Endocrinol 2022; 31:250-255. [DOI: 10.1297/cpe.2022-0030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Accepted: 06/15/2022] [Indexed: 11/04/2022] Open
Affiliation(s)
- Kanako Tanase-Nakao
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan
| | - Koji Muroya
- Department of Endocrinology and Metabolism, Kanagawa Children’s Medical Center, Yokohama, Japan
| | - Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children’s Medical Center, Yokohama, Japan
| | - Kiyomi Abe
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
| | - Tomonobu Hasegawa
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
| | - Satoshi Narumi
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
7
|
Ito N, Kubota T, Kitanaka S, Fujiwara I, Adachi M, Takeuchi Y, Yamagami H, Kimura T, Shinoda T, Minagawa M, Okazaki R, Ozono K, Seino Y, Fukumoto S. Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23. J Bone Miner Metab 2021; 39:1066-1075. [PMID: 34255195 DOI: 10.1007/s00774-021-01250-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/16/2021] [Accepted: 07/04/2021] [Indexed: 12/28/2022]
Abstract
INTRODUCTION Measurement of fibroblast growth factor 23 (FGF23) has been reported to be clinically useful for the differential diagnosis of chronic hypophosphatemia. However, assays for research use only are available in Japan. Thus, the objective of this study was to examine the clinical utility of a novel and automated chemiluminescent enzyme immunoassay for the measurement of FGF23. MATERIALS AND METHODS Participants were recruited from July 2015 to January 2017 at six facilities in Japan. Thirty-eight patients with X-linked hypophosphatemic rickets (XLH 15 males, 23 females, age 0-66 years), five patients with tumour-induced osteomalacia (TIO 3 males, 2 females, age 60-73 years), and twenty-two patients with hypophosphatemia (11 males, 11 females, age 1-75 years) caused due to other factors participated in this study. RESULTS With the clinical cut-off value of FGF23 at 30.0 pg/mL indicated in the Diagnostic Guideline of Rickets/Osteomalacia in Japan, the sensitivity and specificity of FGF23-related hypophosphatemic rickets/osteomalacia without vitamin D deficiency (disease group-1) were 100% and 81.8%, respectively, which distinguished it from non-FGF23-related hypophosphatemia (disease group-2). Furthermore, the diagnostic sensitivity of FGF23-related hypophosphatemia with vitamin D deficiency remained at 100%. Among the four patients with FGF23 levels ≥ 30.0 pg/mL in disease group-2, two patients with relatively higher FGF23 values were suspected to have genuine FGF23-related hypophosphatemia, due to the ectopic production of FGF23 in pulmonary and prostate small cell carcinomas. CONCLUSION The novel FGF23 assay tested in this study is useful for the differential diagnosis of hypophosphatemic rickets/osteomalacia in a clinical setting.
Collapse
Affiliation(s)
- Nobuaki Ito
- Division of Nephrology and Endocrinology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
| | - Takuo Kubota
- Department of Pediatrics, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Sachiko Kitanaka
- Department of Pediatrics, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Ikuma Fujiwara
- Department of Pediatric Endocrinology and Environmental Medicine, Graduate School of Medicine, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan
| | - Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, 2-138-4 Mutsukawa, Minami-ku, Yokohama, Kanagawa, 232-8555, Japan
| | - Yasuhiro Takeuchi
- Endocrine Center, Toranomon Hospital, 2-2-2, Toranomon, Minato-ku, Tokyo, 105-8470, Japan
- Okinaka Memorial Institute for Medical Research, Toranomon, Minato-ku, Tokyo, 105-8470, Japan
| | - Hitomi Yamagami
- Minaris Medical Co., Ltd., 1-8-10 Harumi, Chuo-ku, Tokyo, 104-6004, Japan
| | - Takehide Kimura
- Minaris Medical Co., Ltd., 1-8-10 Harumi, Chuo-ku, Tokyo, 104-6004, Japan
| | - Tatsuya Shinoda
- Minaris Medical Co., Ltd., 1-8-10 Harumi, Chuo-ku, Tokyo, 104-6004, Japan
| | - Masanori Minagawa
- Division of Endocrinology, Chiba Children's Hospital, 579-1 Hetacho, Midoriku, Chiba, 266-0007, Japan
| | - Ryo Okazaki
- Division of Endocrinology and Metabolism, Third Department of Medicine, Teikyo University Chiba Medical Center, Ichihara, Chiba, Japan
| | - Keiichi Ozono
- Department of Pediatrics, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Yoshiki Seino
- Department of Pediatrics, Osaka Hospital, Japan Community Healthcare Organization (JCHO), 4-2-78, Fukushima, Fukushima-ku, Osaka, 553-0003, Japan
| | - Seiji Fukumoto
- Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical Sciences, Tokushima University, 3-18-15, Kuramoto-cho, Tokushima, 770-8503, Japan
| |
Collapse
|
8
|
Kasahara T, Endou S, Osaki S, Kawatani S, Amisaki R, Sasaki N, Mizuta E, Adachi M, Ohtahara A. More than the half number of the severe CAD patients without features of metabolic syndrome had hyperlipoprotein(a)-emia. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
It was reported that insulin suppresses apolipoprotein(a) synthesis in primary cultures of cynomolgus monkey hepatocytes (Neele DM. Diabetologia 1999). Therefore, there is a possibility that inverse association exists between lipoprotein(a); Lp(a) and metabolic syndrome (Mets) with insulin resistance/ hyperinsulinemia for the coronary atherosclerosis.
Purpose
The purpose is to examine the association between Lp(a) and Mets on the CAD patients.
Method
847 male subjects with angiographically demonstrated CAD were enrolled. The subjects were divided into the five groups according to the scored numbers by the counting of Mets components shown below (presence 1, absence 0); 1. BMI ≥25kg/m2, 2. comorbidity of hypertension, 3. triglyceride ≥150mg/dL and/or HDL cholesterol <40mg/dL, 4. fasting plasma glucose ≥110mg/dL and/or comorbidity of diabetes mellitus (Group 0; without any Mets components, Group 4; with all Mets component). The insulin levels (μU/mL) and the prevalence of hyperLp(a)-emia (≥30 mg/dL) were compared between in Group 0 and in Group 4. The blood samples for laboratory tests were collected after an over night fast.
Result
As the scored numbers increased, the insulin levels increased (Group 0; 5.1 μU/mL versus Group 4; 11.4 μU/mL: p<0.0001) and the prevalence of hyperlipoprotein(a)-emia decreased (Group 0; 41.6% versus Group 4; 21.4%: p<0.01). The prevalence of hyperLp(a)-emia increased as the severity of coronary atherosclerosis aggravated (Figure 1; one vessel disease 21.5%, two vessel disease 27.0% three vessel disease 32.1%: one vessel disease versus three vessel disease p<0.01). Especially to limited the three vessel disease subjects (Figure 2), the prevalence of hyperlipoprotein(a)-emia in Group 0 was markedly high (56.7%).
Conclusion
More than the half number of severe CAD patients without features of Mets had hyperLp(a)-emia.
Funding Acknowledgement
Type of funding sources: None. Figure 1Figure 2
Collapse
Affiliation(s)
- T Kasahara
- San-in Rosai Hospital, Division of Cardiology, Yonago, Japan
| | - S Endou
- San-in Rosai Hospital, Division of Cardiology, Yonago, Japan
| | - S Osaki
- San-in Rosai Hospital, Division of Cardiology, Yonago, Japan
| | - S Kawatani
- San-in Rosai Hospital, Division of Cardiology, Yonago, Japan
| | - R Amisaki
- San-in Rosai Hospital, Division of Cardiology, Yonago, Japan
| | - N Sasaki
- San-in Rosai Hospital, Division of Cardiology, Yonago, Japan
| | - E Mizuta
- San-in Rosai Hospital, Division of Cardiology, Yonago, Japan
| | - M Adachi
- San-in Rosai Hospital, Division of Cardiology, Yonago, Japan
| | - A Ohtahara
- San-in Rosai Hospital, Division of Cardiology, Yonago, Japan
| |
Collapse
|
9
|
Iwano R, Toki M, Hanakawa J, Asakura Y, Adachi M, Tanaka Y, Muroya K. Quantification of serum thyroid hormones using tandem mass spectrometry in patients with Down syndrome. Biomed Chromatogr 2021; 36:e5249. [PMID: 34569083 DOI: 10.1002/bmc.5249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2021] [Revised: 09/13/2021] [Accepted: 09/16/2021] [Indexed: 11/05/2022]
Abstract
Thyroid dysfunction is common in patients with Down syndrome (DS), the most common chromosomal disorder. Thyroid hormones (THs) are important for normal growth, neurodevelopment, and metabolism, highlighting the importance of quantifying the levels in patients with DS. However, current methods possess cross-reactivity that results in inaccuracies in quantification. We aimed at developing a new analytical method for quantifying the total 3,3',5-triiodo-l-thyronine (TT3), total 3,3',5,5'-tetraiodo-l-thyronine (TT4), 3,3',5'-triiodo-l-thyronine, and reverse T3 (rT3) levels using LC-MS/MS. Repeatability and reproducibility with coefficient of variation values of 2-9 and 3-13%, respectively, were acceptable, suggesting that the assay was suitable for measuring serum THs. We measured the serum TH levels of patients with DS but without thyroid dysfunction (age, 3-20 years) and compared the levels to those of controls (patients with idiopathic short stature; age, 3-17 years). When TH levels were summarized by age group, the serum TT4 concentrations were not significantly different between the controls and patients with DS across all age groups. Meanwhile, the serum TT3 concentrations differed according to age. In addition, the serum rT3 concentrations were significantly higher in patients with DS than in controls, except for those in the 12-14 age group. We also calculated the T3/T4 and rT3/T4 ratios to elucidate the reason for the higher rT3 in patients with DS; however, no useful findings were obtained. Thus, further investigation is needed to clarify our findings.
Collapse
Affiliation(s)
- Reiko Iwano
- Clinical Research Institute, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Machiko Toki
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan.,Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
| | - Junko Hanakawa
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Yumi Asakura
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Yukichi Tanaka
- Clinical Research Institute, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Koji Muroya
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| |
Collapse
|
10
|
Nagahara K, Nishibukuro T, Ogiwara Y, Ikegawa K, Tada H, Yamagishi M, Kawashiri MA, Ochi A, Toyoda J, Nakano Y, Adachi M, Mizuno K, Hasegawa Y, Dobashi K. Genetic Analysis of Japanese Children Clinically Diagnosed with Familial Hypercholesterolemia. J Atheroscler Thromb 2021; 29:667-677. [PMID: 34011801 PMCID: PMC9135660 DOI: 10.5551/jat.62807] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Aim: This study aimed to elucidate the gene and lipid profiles of children clinically diagnosed with familial hypercholesterolemia (FH).
Methods: A total of 21 dyslipidemia-related Mendelian genes, including FH causative genes (LDLR,APOB, andPCSK9) and LDL-altering genes (APOE,LDLRAP1, andABCG5/8), were sequenced in 33 Japanese children (mean age, 9.7±4.2 years) with FH from 29 families.
Results: Fifteen children (45.5%) with pathogenic variants inLDLR (eight different heterozygous variants) and one child (3.0%) with thePCSK9 variant were found. Among 17 patients without FH causative gene variants, 3 children had variants in LDL-altering genes, anAPOE variant and twoABCG8 variants. The mean serum total cholesterol (280 vs 246 mg/dL), LDL-cholesterol (LDL-C, 217 vs 177 mg/dL), and non-HDL cholesterol (228 vs 188 mg/dL) levels were significantly higher in the pathogenic variant-positive group than in the variant-negative group. In the variant-positive group, 81.3% of patients had LDL-C levels ≥ 180 mg/dL but 35.3% in the variant-negative group. The mean LDL-C level was significantly lower in children with missense variants, especially with the p.Leu568Val variant, than in children with other variants inLDLR, whereas the LDL-altering variants had similar effects on the increase in serum LDL-C toLDLR p.Leu568Val.
Conclusion: Approximately half of the children clinically diagnosed with FH had pathogenic variants in FH causative genes. The serum LDL-C levels tend to be high in FH children with pathogenic variations, and the levels are by the types of variants. Genetic analysis is useful; however, further study on FH without any variants is required.
Collapse
Affiliation(s)
- Keiko Nagahara
- Department of Pediatrics, Showa University School of Medicine
| | - Tsuyoshi Nishibukuro
- Department of Endocrinology and Metabolism, Tokyo Metropolitan Children's Medical Center
| | - Yasuko Ogiwara
- Department of Endocrinology and Metabolism, Tokyo Metropolitan Children's Medical Center
| | - Kento Ikegawa
- Department of Endocrinology and Metabolism, Tokyo Metropolitan Children's Medical Center
| | - Hayato Tada
- Department of Cardiovascular and Internal Medicine. Kanazawa University Graduate School of Medicine
| | - Masakazu Yamagishi
- Department of Cardiovascular and Internal Medicine. Kanazawa University Graduate School of Medicine
| | - Masa-Aki Kawashiri
- Department of Cardiovascular and Internal Medicine. Kanazawa University Graduate School of Medicine
| | - Ayako Ochi
- Department of Pediatrics, Showa University School of Medicine
| | - Junya Toyoda
- Department of Pediatrics, Showa University School of Medicine
| | - Yuya Nakano
- Department of Pediatrics, Showa University School of Medicine
| | - Masanori Adachi
- Department of Pediatrics, Showa University School of Medicine
| | - Katsumi Mizuno
- Department of Pediatrics, Showa University School of Medicine
| | - Yukihiro Hasegawa
- Department of Endocrinology and Metabolism, Tokyo Metropolitan Children's Medical Center
| | - Kazushige Dobashi
- Department of Pediatrics, Showa University School of Medicine.,Department of Pediatrics, School of Medicine, University of Yamanashi
| |
Collapse
|
11
|
Adachi M, Muroya K, Hanakawa J, Asakura Y. Metreleptin worked in a diabetic woman with a history of hematopoietic stem cell transplantation (HSCT) during infancy: further support for the concept of 'HSCT-associated lipodystrophy'. Endocr J 2021; 68:399-407. [PMID: 33229817 DOI: 10.1507/endocrj.ej20-0325] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
A 17-year-old woman with a history of childhood leukemia and hematopoietic stem cell transplantation (HSCT), preceded by total body irradiation, developed diabetes, dyslipidemia, fatty liver, and marked insulin resistance. Based on Dunnigan phenotype, HSCT-associated lipodystrophy was suspected. Because of rapid deterioration of diabetes control, metreleptin was introduced at 23 years of age upon receipt of her caregiver's documented consent. This trial was initially planned as a prospective 18 month-long study, with regular assessments of the patient's physical activity, food intake, and body composition analysis. However, because an abrupt and transient attenuation of the metreleptin effect occurred 16 months after the treatment initiation, the entire course of 28 months is reported here. Over the period, her HbA1c decreased from 10.9% to 6.7% despite no significant increase of physical activity and with a stable food intake. Decreased levels of triglyceride and non-HDL cholesterol were found. Her liver function improved, indicating the amelioration of fatty liver. In addition, a 25% reduction in the subcutaneous fat area at umbilical level was found, accompanied by a decrease in fat percentage of both total-body and trunk. The formation of neutralizing antibodies to metreleptin may be responsible for the transient loss of efficacy, considering a sudden elevation in her serum leptin level. In conclusion, metreleptin is useful for the management of HSCT-associated lipodystrophy, supporting the concept that adipose tissue dysfunction is responsible for diverse post-HSCT metabolic aberrations.
Collapse
Affiliation(s)
- Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama 232-8555, Japan
| | - Koji Muroya
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama 232-8555, Japan
| | - Junko Hanakawa
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama 232-8555, Japan
| | - Yumi Asakura
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama 232-8555, Japan
| |
Collapse
|
12
|
Fujita Y, Nohara T, Takashima S, Natsuga K, Adachi M, Yoshida K, Shinkuma S, Takeichi T, Nakamura H, Wada O, Akiyama M, Ishiko A, Shimizu H. Intravenous allogeneic multilineage-differentiating stress-enduring cells in adults with dystrophic epidermolysis bullosa: a phase 1/2 open-label study. J Eur Acad Dermatol Venereol 2021; 35:e528-e531. [PMID: 33656198 PMCID: PMC8359848 DOI: 10.1111/jdv.17201] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2020] [Revised: 01/20/2021] [Accepted: 02/18/2021] [Indexed: 12/11/2022]
Affiliation(s)
- Y Fujita
- Department of Dermatology, Hokkaido University Graduate School of Medicine and Faculty of Medicine, Sapporo, Japan.,Department of Dermatology, Sapporo City General Hospital, Sapporo, Japan
| | - T Nohara
- Department of Dermatology, Hokkaido University Graduate School of Medicine and Faculty of Medicine, Sapporo, Japan
| | - S Takashima
- Department of Dermatology, Hokkaido University Graduate School of Medicine and Faculty of Medicine, Sapporo, Japan
| | - K Natsuga
- Department of Dermatology, Hokkaido University Graduate School of Medicine and Faculty of Medicine, Sapporo, Japan
| | - M Adachi
- Department of Dermatology, Toho University School of Medicine, Tokyo, Japan
| | - K Yoshida
- Department of Dermatology, Toho University School of Medicine, Tokyo, Japan
| | - S Shinkuma
- Department of Dermatology, Nara Medical University School of Medicine, Kashihara, Japan
| | - T Takeichi
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Nakamura
- Department of Dermatology, Hokkaido University Graduate School of Medicine and Faculty of Medicine, Sapporo, Japan
| | - O Wada
- Life Science Institute Inc., Tokyo, Japan
| | - M Akiyama
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - A Ishiko
- Department of Dermatology, Toho University School of Medicine, Tokyo, Japan
| | - H Shimizu
- Department of Dermatology, Hokkaido University Graduate School of Medicine and Faculty of Medicine, Sapporo, Japan
| |
Collapse
|
13
|
Kasahara T, Endoh S, Ohtahara A, Kawatani S, Amisaki R, Mizuta E, Adachi M, Osaki S. The inverse association between lipoprotein(a) levels and metabolic syndorome and its components on coronary artery disease patients. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Purpose
Neele DM (Diabetologia 1999) showed that insulin suppressed apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes. Therefore, there is a possibility that inverse association exists between lipoprotein(a) [Lp(a)] and metabolic syndorome (Mets) with insulin resistance/hyperinsulinemia for coronary atherosclerosis. Sung KC (Nutr Metab Cardiovasc Dis 2013) described the inverse association between Lp(a) levels and Mets and its components on an asian occupational cohort. And high levels of Lp(a) were associated with preclinical atherosclerosis, as evaluated by coronary calcium score with cardiac computed tomography. There is no similar examination on coronary artery disease (CAD) patients. The purpose is to examine similar considerations on CAD patients.
Method
610 subjects with angiographically demonstrated CAD were enrolled. The patients who receiving medication for dyslipidemia and Insulin administration were excluded. The blood samples for laboratory tests were collected after an over night fast. Subjects were divided into four groups according to quartiles of Lp(a) levels (mg/dL). Ranges of quartile groups of Lp(a) were Q1: <9.0, Q2: 9.0–<16.0, Q3: 16.0–<30.0, Q4: ≥30.0.
Results
The inverse association Lp(a) levels and Mets and its component. The comparison of Q1 (bottom quartile) versus Q4 (top quartile) was shown below; the comorbidity rate of Mets 19.5% versus 8.0% (p<0.01), BMI (kg/m2) 23.5 versus 22.7 (p<0.05), trigyceride (mg/dL) 144.0 versus 107.5 (p<0.0001), HDL cholesterol (mg/dL) 46.8 versus 50.7 (p<0.05), the comorbidity rate of hypertension 60.4% versus 50.7% (p=0.084), glucose (mg/dL) 107.1 versus 100.6 (p<0.05), insulin (μU/mL) 8.49 versus 5.85 (p<0.0001), HOMA-R 2.26 versus 1.44 (p<0.0001). The mean number of diseased coronary vessel was higher in the Q4 group (2.07) than in the Q1 group (1.87) (p<0.05).
Conclusion
There was the inverse association between Lp(a) levels and Mets and its components on CAD patients. The robust association was found between Lp(a) levels and severity of coronary atherosclerosis despite this inverse correlation.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- T Kasahara
- San-in Rosai Hospital, Division of Cardiology, Yonago, Japan
| | - S Endoh
- San-in Rosai Hospital, Division of Cardiology, Yonago, Japan
| | - A Ohtahara
- San-in Rosai Hospital, Division of Cardiology, Yonago, Japan
| | - S Kawatani
- San-in Rosai Hospital, Division of Cardiology, Yonago, Japan
| | - R Amisaki
- San-in Rosai Hospital, Division of Cardiology, Yonago, Japan
| | - E Mizuta
- San-in Rosai Hospital, Division of Cardiology, Yonago, Japan
| | - M Adachi
- San-in Rosai Hospital, Division of Cardiology, Yonago, Japan
| | - S Osaki
- San-in Rosai Hospital, Division of Cardiology, Yonago, Japan
| |
Collapse
|
14
|
Iwahashi-Odano M, Nagasaki K, Fukami M, Nishioka J, Yatsuga S, Asakura Y, Adachi M, Muroya K, Hasegawa T, Narumi S. Congenital Hypothyroidism Due to Truncating PAX8 Mutations: A Case Series and Molecular Function Studies. J Clin Endocrinol Metab 2020; 105:5897054. [PMID: 32841355 DOI: 10.1210/clinem/dgaa584] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Accepted: 08/20/2020] [Indexed: 11/19/2022]
Abstract
CONTEXT PAX8 is a transcription factor required for thyroid development, and its mutation causes congenital hypothyroidism (CH). More than 20 experimentally verified loss-of-function PAX8 mutations have been described, and all but one were located in the DNA-binding paired domain. OBJECTIVE We report the identification and functional characterization of 3 novel truncating PAX8 mutations located outside the paired domain. METHODS Three CH probands, diagnosed in the frame of newborn screening, had thyroid hypoplasia and were treated with levothyroxine. Next-generation sequencing-based mutation screening was performed. Functionality of the identified mutations were verified with Western blotting, intracellular localization assays, and transactivation assays with use of HeLa cells. Luciferase complementation assays were used to evaluate the effect of mutations on the interaction between PAX8 and its partner, NKX2-1. RESULTS Each proband had novel truncating PAX8 mutations that were I160Sfs*52, Q213Efs*27, and F342Rfs*85. Western blotting showed destabilization of the I160fs-PAX8 protein. Q213fs-PAX8 and F342fs-PAX8 showed normal protein expression levels and normal nuclear localization, but showed loss of transactivation of the luciferase reporter. By luciferase complementation assays, we showed that PAX8-NKX2-1 interaction was defective in Q213fs-PAX8. We also characterized the recombinant PAX8 proteins, and found that the protein sequence corresponding to exon 10 (363-400 aa residues) was essential for the PAX8-NKX2-1 interaction. CONCLUSIONS Clinical and molecular findings of 3 novel truncating PAX8 mutations located outside the paired domain were reported. Experiments using cultured cells and recombinant proteins showed that the C-terminal portion (ie, 363-400 aa) of PAX8 is required for the PAX8-NKX2-1 interaction.
Collapse
Affiliation(s)
- Megumi Iwahashi-Odano
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan
- Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan
| | - Keisuke Nagasaki
- Division of Pediatrics, Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Maki Fukami
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan
| | - Junko Nishioka
- Department of Pediatrics and Child Health, Kurume University School of Medicine, Fukuoka, Japan
| | - Shuichi Yatsuga
- Department of Pediatrics and Child Health, Kurume University School of Medicine, Fukuoka, Japan
| | - Yumi Asakura
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Koji Muroya
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Tomonobu Hasegawa
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
| | - Satoshi Narumi
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
15
|
Murakami T, Sato T, Adachi M, Shichiji M, Ishiguro K, Kihara Y, Nagata S, Ishigaki K. CONGENITAL MUSCULAR DYSTROPHIES. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
16
|
Mizuno H, Takayama E, Satoh A, Into T, Adachi M, Ekuni D, Yashiro K, Mizuno-Kamiya M, Nagayama M, Saku S, Tomofuji T, Doi Y, Murakami Y, Kondoh N, Morita M. Horseradish peroxidase interacts with the cell wall peptidoglycans on oral bacteria. Exp Ther Med 2020; 20:2822-2827. [PMID: 32765778 DOI: 10.3892/etm.2020.9016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Accepted: 11/23/2018] [Indexed: 11/06/2022] Open
Abstract
Salivary peroxidase and myeloperoxidase are known to display antibacterial activity against oral microbes, and previous indications have pointed to the possibility that horseradish peroxidase (HRP) adsorbs onto the membrane of the major oral streptococci, Streptococcus mutans and Streptococcus sanguinis (S. sanguinis). However, the mechanism of interaction between HRP and the bacterial cell wall component is unclear. Dental plaques containing salivary glycoproteins and extracellular microbial products are visualized with 'dental plaque disclosing agent', and are controlled within dental therapy. However, current 'dental plaque disclosing agents' are difficult to evaluate with just dental plaques, since they stain and disclose not only dental plaques but also pellicle formed with salivary glycoproteins on a tooth surface. In this present study, we have demonstrated that HRP interacted with the cell wall component of the major gram-positive bacterial peptidoglycan, but not the major cell wall component of gram-negative bacteria lipopolysaccharide. Furthermore, we observed that the adsorbed HRP labeled with fluorescence was detected on the major oral gram-positive strains S. sanguinis and Streptococcus salivarius (S. salivarius), but not on a gram-negative strain, Escherichia coli (E. coli). Furthermore, we have demonstrated that the combination of HRP and chromogenic substrate clearly disclosed the dental plaques and the biofilm developed by S. sanguinis, S. salivarius and the major gram-postive bacteria Lactobacillus casei on tooth surfaces, and slightly disclosed the biofilm by E. coli. The combination of HRP and chromogenic substrate did not stain either the dental pellicle with the salivary glycoprotein mucin, or naked tooth surfaces. These results have suggested the possibility that the adsorption activity of HRP not only contributes to the evaluation of dental plaque, but that enzymatic activity of HRP may also contribute to improve dental hygiene.
Collapse
Affiliation(s)
- Hirofumi Mizuno
- Department of Preventive Dentistry, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.,Department of Oral Biochemistry, Asahi University School of Dentistry, Mizuho, Gifu 501-0296, Japan
| | - Eiji Takayama
- Department of Oral Biochemistry, Asahi University School of Dentistry, Mizuho, Gifu 501-0296, Japan
| | - Ayano Satoh
- Department of Medical Bioengineering, Graduate School of Interdisciplinary Science and Engineering in Healthcare Systems, Okayama University, Okayama 700-8530, Japan
| | - Takeshi Into
- Department of Oral Microbiology, Asahi University School of Dentistry, Mizuho, Gifu 501-0296, Japan
| | - Masanori Adachi
- Department of Dental Materials Science, Asahi University School of Dentistry, Mizuho, Gifu 501-0296, Japan
| | - Daisuke Ekuni
- Department of Preventive Dentistry, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan
| | - Koji Yashiro
- Department of Oral Biochemistry, Asahi University School of Dentistry, Mizuho, Gifu 501-0296, Japan.,Department of Chemistry, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan
| | - Masako Mizuno-Kamiya
- Department of Oral Biochemistry, Asahi University School of Dentistry, Mizuho, Gifu 501-0296, Japan.,Chemistry Laboratory, Department of Bussiness Administration, Asahi University School of Business Administration, Mizuho, Gifu 501-0296, Japan
| | - Motohiko Nagayama
- Department of Oral Pathology, Asahi University School of Dentistry, Mizuho, Gifu 501-0296, Japan
| | - Seitaro Saku
- Department of Operative Dentistry, Asahi University School of Dentistry, Mizuho, Gifu 501-0296, Japan
| | - Takaaki Tomofuji
- Department of Preventive Dentistry, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.,Community Oral Health, Asahi University School of Dentistry, Mizuho, Gifu 501-0296, Japan
| | - Yutaka Doi
- Department of Dental Materials Science, Asahi University School of Dentistry, Mizuho, Gifu 501-0296, Japan
| | - Yukitaka Murakami
- Department of Oral Microbiology, Asahi University School of Dentistry, Mizuho, Gifu 501-0296, Japan
| | - Nobuo Kondoh
- Department of Oral Biochemistry, Asahi University School of Dentistry, Mizuho, Gifu 501-0296, Japan
| | - Manabu Morita
- Department of Preventive Dentistry, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan
| |
Collapse
|
17
|
Adachi M, Tajima T, Muroya K. Correction to: Dietary potassium restriction attenuates urinary sodium wasting in the generalized form of pseudohypoaldosteronism type 1. CEN Case Rep 2020; 9:294. [PMID: 32350769 DOI: 10.1007/s13730-020-00477-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
In the Original publication of the article, there are two minor errors in Fig. 2 and these include one missing arrow in Fig. 2d and appears as an incorrectly drawn solid lines as dashed line in Fig. 2d.
Collapse
Affiliation(s)
- Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Mutsukawa, 2‑138‑4, Minami‑ku, Yokohama, 232‑8555, Japan.
| | - Toshihiro Tajima
- Department of Pediatrics, Jichi Children's Hospital Medical Center Tochigi, Tochigi, Japan
| | - Koji Muroya
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Mutsukawa, 2‑138‑4, Minami‑ku, Yokohama, 232‑8555, Japan
| |
Collapse
|
18
|
Minamihata K, Tsukamoto K, Adachi M, Shimizu R, Mishina M, Kuroki R, Nagamune T. Genetically fused charged peptides induce rapid crystallization of proteins. Chem Commun (Camb) 2020; 56:3891-3894. [PMID: 32134050 DOI: 10.1039/c9cc09529b] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
We utilized electrostatic interaction to induce rapid crystallization of streptavidin. Simply mixing streptavidins possessing either a positively or negatively charged peptide at their C-terminus generated diffraction-quality crystals in a few hours. We modified the streptavidin crystals with fluorescent molecules using biotin, demonstrating the concept of protein crystals as functional biomaterials.
Collapse
Affiliation(s)
- K Minamihata
- Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, 744 Motooka, Fukuoka, 819-0395, Japan.
| | | | | | | | | | | | | |
Collapse
|
19
|
Adachi M. A 10-year, single-center, retrospective, observational study of 11 patients infected with Pasteurella multocida in Japan. J Infect Public Health 2020. [DOI: 10.1016/j.jiph.2020.01.183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
20
|
Kubota T, Adachi M, Kitaoka T, Hasegawa K, Ohata Y, Fujiwara M, Michigami T, Mochizuki H, Ozono K. Clinical Practice Guidelines for Achondroplasia. Clin Pediatr Endocrinol 2020; 29:25-42. [PMID: 32029970 PMCID: PMC6958518 DOI: 10.1297/cpe.29.25] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Accepted: 08/07/2019] [Indexed: 12/04/2022] Open
Abstract
Achondroplasia (ACH) is a skeletal dysplasia that presents with limb shortening, short
stature, and characteristic facial configuration. ACH is caused by mutations of the
FGFR3 gene, leading to constantly activated FGFR3 and activation of its
downstream intracellular signaling pathway. This results in the suppression of chondrocyte
differentiation and proliferation, which in turn impairs endochondral ossification and
causes short-limb short stature. ACH also causes characteristic clinical symptoms,
including foramen magnum narrowing, ventricular enlargement, sleep apnea, upper airway
stenosis, otitis media, a narrow thorax, spinal canal stenosis, spinal kyphosis, and
deformities of the lower extremities. Although outside Japan, papers on health supervision
are available, they are based on reports and questionnaire survey results. Considering the
scarcity of high levels of evidence and clinical guidelines for patients with ACH,
clinical practical guidelines have been developed to assist both healthcare professionals
and patients in making appropriate decisions in specific clinical situations. Eleven
clinical questions were established and a systematic literature search was conducted using
PubMed/MEDLINE. Evidence-based recommendations were developed, and the guidelines describe
the recommendations related to the clinical management of ACH. We anticipate that these
clinical practice guidelines for ACH will be useful for healthcare professionals and
patients alike.
Collapse
Affiliation(s)
- Takuo Kubota
- Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.,Guidelines Development Committee for Achondroplasia
| | - Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan.,Guidelines Development Committee for Achondroplasia
| | - Taichi Kitaoka
- Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.,Guidelines Development Committee for Achondroplasia
| | - Kosei Hasegawa
- Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmacological Sciences, Okayama, Japan.,Guidelines Development Committee for Achondroplasia
| | - Yasuhisa Ohata
- Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.,Guidelines Development Committee for Achondroplasia
| | - Makoto Fujiwara
- Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.,Guidelines Development Committee for Achondroplasia
| | - Toshimi Michigami
- Department of Bone and Mineral Research, Research Institute, Osaka Women's and Children's Hospital, Osaka Prefectural Hospital Organization, Osaka, Japan.,Guidelines Development Committee for Achondroplasia
| | - Hiroshi Mochizuki
- Division of Endocrinology and Metabolism, Saitama Children's Medical Center, Saitama, Japan.,Guidelines Development Committee for Achondroplasia
| | - Keiichi Ozono
- Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.,Guidelines Development Committee for Achondroplasia
| |
Collapse
|
21
|
Michigami T, Ohata Y, Fujiwara M, Mochizuki H, Adachi M, Kitaoka T, Kubota T, Sawai H, Namba N, Hasegawa K, Fujiwara I, Ozono K. Clinical Practice Guidelines for Hypophosphatasia. Clin Pediatr Endocrinol 2020; 29:9-24. [PMID: 32029969 PMCID: PMC6958520 DOI: 10.1297/cpe.29.9] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/23/2019] [Accepted: 08/16/2019] [Indexed: 12/17/2022] Open
Abstract
Hypophosphatasia (HPP) is a rare bone disease caused by inactivating mutations in the
ALPL gene, which encodes tissue-nonspecific alkaline phosphatase
(TNSALP). Patients with HPP have varied clinical manifestations and are classified based
on the age of onset and severity. Recently, enzyme replacement therapy using bone-targeted
recombinant alkaline phosphatase (ALP) has been developed, leading to improvement in the
prognosis of patients with life-threatening HPP. Considering these recent advances,
clinical practice guidelines have been generated to provide physicians with guides for
standard medical care for HPP and to support their clinical decisions. A task force was
convened for this purpose, and twenty-one clinical questions (CQs) were formulated,
addressing the issues of clinical manifestations and diagnosis (7 CQs) and those of
management and treatment (14 CQs). A systematic literature search was conducted using
PubMed/MEDLINE, and evidence-based recommendations were developed. The guidelines have
been modified according to the evaluations and suggestions from the Clinical Guideline
Committee of The Japanese Society for Pediatric Endocrinology (JSPE) and public comments
obtained from the members of the JSPE and a Japanese HPP patient group, and then approved
by the Board of Councils of the JSPE. We anticipate that the guidelines will be revised
regularly and updated.
Collapse
Affiliation(s)
- Toshimi Michigami
- Department of Bone and Mineral Research, Research Institute, Osaka Women's and Children's Hospital, Osaka Prefectural Hospital Organization, Osaka, Japan.,Task Force for Hypophosphatasia Guidelines
| | - Yasuhisa Ohata
- Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.,Task Force for Hypophosphatasia Guidelines
| | - Makoto Fujiwara
- Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.,Task Force for Hypophosphatasia Guidelines
| | - Hiroshi Mochizuki
- Division of Endocrinology and Metabolism, Saitama Children's Medical Center, Saitama, Japan.,Task Force for Hypophosphatasia Guidelines
| | - Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Kanagawa, Japan.,Task Force for Hypophosphatasia Guidelines
| | - Taichi Kitaoka
- Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.,Task Force for Hypophosphatasia Guidelines
| | - Takuo Kubota
- Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.,Task Force for Hypophosphatasia Guidelines
| | - Hideaki Sawai
- Department of Obstetrics and Gynecology, Hyogo College of Medicine, Hyogo, Japan.,Task Force for Hypophosphatasia Guidelines
| | - Noriyuki Namba
- Division of Pediatrics and Perinatology, Tottori University Faculty of Medicine, Tottori, Japan.,Task Force for Hypophosphatasia Guidelines
| | - Kosei Hasegawa
- Department of Pediatrics, Okayama University Hospital, Okayama, Japan.,Task Force for Hypophosphatasia Guidelines
| | - Ikuma Fujiwara
- Department of Pediatrics, Sendai City Hospital, Miyagi, Japan.,Task Force for Hypophosphatasia Guidelines
| | - Keiichi Ozono
- Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.,Task Force for Hypophosphatasia Guidelines
| |
Collapse
|
22
|
Adachi M, Tajima T, Muroya K. Dietary potassium restriction attenuates urinary sodium wasting in the generalized form of pseudohypoaldosteronism type 1. CEN Case Rep 2020; 9:133-137. [PMID: 31900739 DOI: 10.1007/s13730-019-00441-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2019] [Accepted: 12/15/2019] [Indexed: 10/25/2022] Open
Abstract
Owing to its rarity and severe nature, the treatment for generalized pseudohypoaldosteronism type 1 (PHA1), a genetic disorder in the epithelial sodium channel (ENaC), is exclusively experience-based. In particular, the usefulness of dietary potassium restriction in PHA1 remains unclear with the absence of theoretical background to elucidate its utility. First, we demonstrated the effect of potassium restriction in a 13-month-old patient with ENaC γ-subunit gene mutations via a retrospective chart review; reduction of daily dietary potassium intake from 40 to 20 mEq induced rapid restoration of volume depletion, as evidenced by weight gain, elevation of the serum sodium level from 133 to 141 mEq/L, decreased urinary sodium excretion, and normalized renin activity. The serum potassium level decreased from 5.6 to 4.5 mEq/L. Next, we attempted to elucidate the pathophysiological basis of the usefulness of potassium restriction, leveraged by the increased knowledge regarding the roles of with-no-lysine kinases (WNKs) in the distal nephron. When potassium is restricted, the WNK signal will turn "on" in the distal nephron via reduction in the intracellular chloride level. Consequently, the sodium reabsorption from the Na+Cl- cotransporter (NCC) in the distal convoluted tubule and possibly from pendrin in the β-intercalated cell will increase. Thus, potassium restriction causes NCC and pendrin to compensate for the non-functional ENaC in the collecting duct. In conclusion, dietary potassium restriction is one of the indispensable treatments for generalized PHA1.
Collapse
Affiliation(s)
- Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Mutsukawa, 2-138-4, Minami-ku, Yokohama, 232-8555, Japan.
| | - Toshihiro Tajima
- Department of Pediatrics, Jichi Children's Hospital Medical Center Tochigi, Tochigi, Japan
| | - Koji Muroya
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Mutsukawa, 2-138-4, Minami-ku, Yokohama, 232-8555, Japan
| |
Collapse
|
23
|
Itoh Y, Uenohara S, Adachi M, Morie T, Aihara K. Reconstructing bifurcation diagrams only from time-series data generated by electronic circuits in discrete-time dynamical systems. Chaos 2020; 30:013128. [PMID: 32013489 DOI: 10.1063/1.5119187] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Accepted: 12/30/2019] [Indexed: 06/10/2023]
Abstract
Bifurcation-diagram reconstruction estimates various attractors of a system without observing all of them but only from observing several attractors with different parameter values. Therefore, the bifurcation-diagram reconstruction can be used to investigate how attractors change with the parameter values, especially for real-world engineering and physical systems for which only a limited number of attractors can be observed. Although bifurcation diagrams of various systems have been reconstructed from time-series data generated in numerical experiments, the systems that have been targeted for reconstructing bifurcation diagrams from time series measured from physical phenomena so far have only been continuous-time dynamical systems. In this paper, we reconstruct bifurcation diagrams only from time-series data generated by electronic circuits in discrete-time dynamical systems with different parameter values. The generated time-series datasets are perturbed by dynamical noise and contaminated by observational noise. To reconstruct the bifurcation diagrams only from the time-series datasets, we use an extreme learning machine as a time-series predictor because it has a good generalization property. Hereby, we expect that the bifurcation-diagram reconstruction with the extreme learning machine is robust against dynamical noise and observational noise. For quantitatively verifying the robustness, the Lyapunov exponents of the reconstructed bifurcation diagrams are compared with those of the bifurcation diagrams generated in numerical experiments and by the electronic circuits.
Collapse
Affiliation(s)
- Y Itoh
- Department of Electrical and Electronic Engineering, Hokkaido University of Science, Hokkaido 006-8585, Japan
| | - S Uenohara
- Institute of Industrial Science, The University of Tokyo, Tokyo 153-8505, Japan
| | - M Adachi
- Department of Electrical and Electronic Engineering, Tokyo Denki University, Tokyo 120-8551, Japan
| | - T Morie
- Department of Human Intelligence Systems, Kyushu Institute of Technology, Kitakyushu 808-0196, Japan
| | - K Aihara
- Institute of Industrial Science, The University of Tokyo, Tokyo 153-8505, Japan
| |
Collapse
|
24
|
Sugisawa C, Takamizawa T, Abe K, Hasegawa T, Shiga K, Sugawara H, Ohsugi K, Muroya K, Asakura Y, Adachi M, Daitsu T, Numakura C, Koike A, Tsubaki J, Kitsuda K, Matsuura N, Taniyama M, Ishii S, Satoh T, Yamada M, Narumi S. Genetics of Congenital Isolated TSH Deficiency: Mutation Screening of the Known Causative Genes and a Literature Review. J Clin Endocrinol Metab 2019; 104:6229-6237. [PMID: 31504637 DOI: 10.1210/jc.2019-00657] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2019] [Accepted: 07/18/2019] [Indexed: 01/10/2023]
Abstract
CONTEXT Congenital isolated TSH deficiency (i-TSHD) is a rare form of congenital hypothyroidism. Five genes (IGSF1, IRS4, TBL1X, TRHR, and TSHB) responsible for the disease have been identified, although their relative frequencies and hypothalamic/pituitary unit phenotypes have remained to be clarified. OBJECTIVES To define the relative frequencies and hypothalamic/pituitary unit phenotypes of congenital i-TSHD resulting from single gene mutations. PATIENTS AND METHODS Thirteen Japanese patients (11 boys and 2 girls) with congenital i-TSHD were enrolled. IGSF1, IRS4, TBL1X, TRHR, and TSHB were sequenced. For a TBL1X mutation (p.Asn382del), its pathogenicity was verified in vitro. For a literature review, published clinical data derived from 74 patients with congenital i-TSHD resulting from single-gene mutations were retrieved and analyzed. RESULTS Genetic screening of the 13 study subjects revealed six mutation-carrying patients (46%), including five hemizygous IGSF1 mutation carriers and one hemizygous TBL1X mutation carrier. Among the six mutation carriers, one had intellectual disability and the other one had obesity, but the remaining four did not show nonendocrine phenotypes. Loss of function of the TBL1X mutation (p.Asn382del) was confirmed in vitro. The literature review demonstrated etiology-specific relationship between serum prolactin (PRL) levels and TRH-stimulated TSH levels with some degree of overlap. CONCLUSIONS The mutation screening study covering the five causative genes of congenital i-TSHD was performed, showing that the IGSF1 defect was the leading genetic cause of the disease. Assessing relationships between serum PRL levels and TRH-stimulated TSH levels would contribute to predict the etiologies of congenital i-TSHD.
Collapse
Affiliation(s)
- Chiho Sugisawa
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan
| | - Tetsuya Takamizawa
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Kiyomi Abe
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
| | - Tomonobu Hasegawa
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
| | - Kentaro Shiga
- Children's Medical Center, Yokohama City University Medical Center, Yokohama, Japan
| | - Hidenori Sugawara
- Children's Medical Center, Yokohama City University Medical Center, Yokohama, Japan
| | - Koji Ohsugi
- Children's Medical Center, Yokohama City University Medical Center, Yokohama, Japan
| | - Koji Muroya
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Yumi Asakura
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Takashi Daitsu
- Department of Pediatrics, Yamagata University School of Medicine, Yamagata, Japan
| | - Chikahiko Numakura
- Department of Pediatrics, Yamagata University School of Medicine, Yamagata, Japan
| | | | - Junko Tsubaki
- Department of Pediatrics, Japan Community Health Care Organization Hokkaido Hospital, Hokkaido, Japan
| | - Kazuteru Kitsuda
- Department of Pediatrics, Kitasato University School of Medicine, Kanagawa, Japan
| | - Nobuo Matsuura
- Department of Pediatrics, Kitasato University School of Medicine, Kanagawa, Japan
- Department of Pediatrics, Bibai Municipal Hospital, Hokkaido, Japan
| | - Matsuo Taniyama
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan
| | - Sumiyasu Ishii
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Tetsurou Satoh
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Masanobu Yamada
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Satoshi Narumi
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan
| |
Collapse
|
25
|
Adachi M, Takamasu T, Inuo C. Hyponatremia secondary to severe atopic dermatitis in early infancy. Pediatr Int 2019; 61:544-550. [PMID: 30985043 DOI: 10.1111/ped.13865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2019] [Revised: 02/27/2019] [Accepted: 04/08/2019] [Indexed: 11/28/2022]
Abstract
BACKGROUND Infants with atopic dermatitis who developed hyponatremia and hyperkalemia with raised aldosterone have been repeatedly described in the Japanese-language literature, but similar reports from other countries are scarce. METHODS We collected reports of atopic dermatitis complicated with hyponatremia (≤130 mEq/L), written either in English or in Japanese, to delineate the characteristics and to elucidate the pathophysiology of this condition. RESULTS Of a total of 36 patients, 35 were Japanese. All patients were infants younger than 9 months. Mean height SD score (SDS) at presentation was -2.1 ± 1.4 (n = 25), with mean body mass index 14.1 ± 1.7 kg/m2 (n = 28). Mean sodium was 120.7 ± 6.1 mEq/L. While 28 patients had hyperkalemia, seven patients had normokalemia. Elevated aldosterone was documented in 15 patients. Nutrition mainly with breast-feeding (97%), parental refusal of steroid ointment (77%), and the association of hypoalbuminemia (73%) were frequent findings. Diminished urinary sodium was verified in all 12 patients tested, indicating that sodium loss from the skin exudates, with limited supply of sodium from breast milk, is the primary cause of hyponatremia. Hyperkalemia seems to result from decreased delivery of sodium to the distal nephron and from the mechanism of the so-called "aldosterone paradox", which inhibits potassium secretion. In addition, physiological aldosterone insensitivity during infancy, low muscle volume, and impaired Na+ ,K+ -ATPase function due to protein deficiency seems to exaggerate the hyperkalemia. CONCLUSIONS Hyponatremia secondary to severe atopic dermatitis is an age-dependent manifestation, elicited by inappropriate treatment that leads to sodium loss from the damaged skin and resultant hyperkalemia via multifaceted mechanisms.
Collapse
Affiliation(s)
- Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan
| | - Tetsuya Takamasu
- Department of Allergy, Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan
| | - Chisato Inuo
- Department of Allergy, Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan
| |
Collapse
|
26
|
Numakura C, Tamiya G, Ueki M, Okada T, Maisawa SI, Kojima-Ishii K, Murakami J, Horikawa R, Tokuhara D, Ito K, Adachi M, Abiko T, Mitsui T, Hayasaka K. Growth impairment in individuals with citrin deficiency. J Inherit Metab Dis 2019; 42:501-508. [PMID: 30715743 DOI: 10.1002/jimd.12051] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/08/2018] [Accepted: 01/04/2019] [Indexed: 11/06/2022]
Abstract
Citrin deficiency causes neonatal intrahepatic cholestasis (NICCD), failure to thrive and dyslipidemia (FTTDCD), and adult-onset type II citrullinemia (CTLN2). Owing to a defect in the NADH-shuttle, citrin deficiency impairs hepatic glycolysis and de novo lipogenesis leading to hepatic energy deficit. To investigate the physiological role of citrin, we studied the growth of 111 NICCD-affected subjects (51 males and 60 females) and 12 NICCD-unaffected subjects (five males and seven females), including the body weight, height, and genotype. We constructed growth charts using the lambda-mu-sigma (LMS) method. The NICCD-affected subjects showed statistically significant growth impairment, including low birth weight and length, low body weight until 6 to 9 months of age, low height until 11 to 13 years of age, and low body weight in 7 to 12-year-old males and 8-year-old females. NICCD-unaffected subjects showed similar growth impairment, including low birth weight and height, and growth impairment during adolescence. In the third trimester, de novo lipogenesis is required for deposition of body fat and myelination of the developing central nervous system, and its impairment likely causes low birth weight and length. The growth rate is the highest during the first 6 months of life and slows down after 6 months of age, which is probably associated with the onset and recovery of NICCD. Adolescence is the second catch-up growth period, and the proportion and distribution of body fat change depending on age and sex. Characteristic growth impairment in citrin deficiency suggests a significant role of citrin in the catch-up growth via lipogenesis.
Collapse
Affiliation(s)
- Chikahiko Numakura
- Department of Pediatrics, Yamagata University School of Medicine, Yamagata, Japan
| | - Gen Tamiya
- Tohoku Medical Megabank Organization, Tohoku University, Miyagi, Japan
- Statistical Genetics Team, RIKEN Center for Advanced Intelligence Project, Tokyo, Japan
| | - Masao Ueki
- Statistical Genetics Team, RIKEN Center for Advanced Intelligence Project, Tokyo, Japan
| | - Tomoo Okada
- Department of Nutrition and Health Science, Kanagawa Institute of Technology, Kanagawa, Japan
| | - Shun-Ichi Maisawa
- Department of Pediatrics, Morioka Children's Hospital, Morioka, Japan
| | - Kanako Kojima-Ishii
- Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Jun Murakami
- Division of Pediatrics and Perinatology, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Reiko Horikawa
- Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan
| | - Daisuke Tokuhara
- Department of Pediatrics, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - Koichi Ito
- Department of Pediatrics and Neonatology, Graduate School of Medical, Sciences, Nagoya City University, Nagoya, Japan
| | - Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Takahiro Abiko
- Department of Pediatrics, Yamagata University School of Medicine, Yamagata, Japan
| | - Tetsuo Mitsui
- Department of Pediatrics, Yamagata University School of Medicine, Yamagata, Japan
| | - Kiyoshi Hayasaka
- Department of Pediatrics, Yamagata University School of Medicine, Yamagata, Japan
- Department of Pediatrics, Miyukikai Hospital, Kaminoyama, Japan
| |
Collapse
|
27
|
Adachi M, Fukami M, Kagami M, Sho N, Yamazaki Y, Tanaka Y, Asakura Y, Hanakawa J, Muroya K. Severe in utero under-virilization in a 46,XY patient with Silver-Russell syndrome with 11p15 loss of methylation. J Pediatr Endocrinol Metab 2019; 32:191-196. [PMID: 30676999 DOI: 10.1515/jpem-2018-0464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/24/2018] [Accepted: 12/16/2018] [Indexed: 11/15/2022]
Abstract
Background Silver-Russell syndrome (SRS) is characterized by growth retardation and variable features including macrocephaly, body asymmetry, and genital manifestations such as cryptorchidism in 46,XY patients. Case presentation The patient was born at 39 weeks with a birth weight of 1344 g. Subtle clitoromegaly warranted a thorough evaluation, which disclosed 46,XY karyotype, bilateral undescended testes, and a rudimentary uterus. Because of severe under-virilization, the patient was assigned as female. Failure to thrive, macrocephaly, and body asymmetry led to the diagnosis of SRS, confirmed by marked hypomethylation of H19/IGF2 intergenic differentially methylated region (IG-DMR). From age 9 years, progressive virilization occurred, which necessitated luteinizing hormone-releasing hormone analog (LHRHa) treatment. Gonadal resection at 15 years revealed immature testes with mostly Sertoli-cell-only tubules. Panel analysis for 46,XY-differences of sex development (DSD) failed to detect any pathogenic variants. Conclusions This is the second reported case of molecularly proven 46,XY SRS accompanied by severe under-virilization. SRS should be included in the differential diagnosis of 46,XY-DSD.
Collapse
Affiliation(s)
- Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Maki Fukami
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan
| | - Masayo Kagami
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan
| | - Noriko Sho
- Department of Child and Adolescent Psychiatry, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Yuichiro Yamazaki
- Department of Urology, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Yukichi Tanaka
- Division of Diagnostic Pathology, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Yumi Asakura
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Junko Hanakawa
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Koji Muroya
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| |
Collapse
|
28
|
Niikura N, Nakatukasa K, Amamiya T, Watanabe KI, Hata H, Kikawa Y, Taniike N, Yamanaka T, Mitsunaga S, Nakagami K, Adachi M, Kondo N, Horii K, Hayashi N, Naito M, Kashiwabara K, Yamashita T, Umeda M, Mukai H, Ota Y. Abstract P1-11-01: Oral care evaluation to prevent oral mucositis in estrogen receptor positive metastatic breast cancer patients treated with everolimus (Oral Care-BC): A randomized controlled phase III trial. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-11-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Oral mucositis is a clinically significant complication of mucotoxic cancer therapy. The incidence of oral mucositis (any grade) as an adverse drug reaction of everolimus is 58%, while an analysis of Asian people has reported its occurrence as 81%.This study hypothesizes that the occurrence of oral mucositis will reduce with professional oral care (POC) administered prior to everolimus treatment.
Method:
This was a randomized, multi-center, open-label, phase III study, to evaluate the efficacy of POC in preventing mucositis induced by everolimus in postmenopausal, estrogen receptor (ER)-positive, metastatic breast cancer patients. Patients were randomized into POC and control groups (1:1 ratio). All patients received everolimus with exemestane and continued the everolimus until disease progression. In the POC group, patients were subjected to teeth surface cleaning, scaling and tongue cleaning, before initiating everolimus, and continued to receive weekly POC from dentist or oral surgeons throughout the 8 weeks of treatment. In the control group, patients brushed their own teeth and gargled with 0.9% sodium chloride solution or water. The primary end-point was to measure the incidence of all grades of oral mucositis. Target accrual was 200 patients with a 2-sided type I error rate of 5% and 80% power to detect 25% risk reduction. This trial has been registered at ClinicalTrials.gov, number NCT 02069093.
Result:
Between May 26, 2014 and Dec 28, 2017, we enrolled 174 women from 31 institutions; 168 were evaluable for efficacy but 5 were excluded (had not received the protocol treatment [n=4]; no efficacy data [n=1]). In 8 weeks, the incidence of grade 1 oral mucositis was significantly different between the POC group (76.5%, 62 of 81 patients) and control group (89.7%, 78 of 87 patients) (p=0.035). The incidence of grade 2 (severe) oral mucositis was also significantly different between the POC group (34.6%, 28 of 81 patients) and control group (54%, 47 of 87 patients) (p= 0.015). As a result of oral mucositis, 18 (22.2%) patients in the POC group and 28 (32.2%) in the control group had to undergo everolimus dose reduction.
Conclusion:
POC reduced the incidence and severity of oral mucositis in patients receiving everolimus and exemestane. This could be a new standard in oral care for patients undergoing this treatment.
Primary Analysis: Incidence Probability of Oral Mucositis POC Group (n=81) Controll (n=87)P-valuneOral Mucositis over Grade1n% n% Yes6276.5 7889.70.035No1923.5 910.3 Risk Difference, % (95% CI)-11.83 (-22.80, -0.85) POC: Professional oral Care
Citation Format: Niikura N, Nakatukasa K, Amamiya T, Watanabe K-i, Hata H, Kikawa Y, Taniike N, Yamanaka T, Mitsunaga S, Nakagami K, Adachi M, Kondo N, Horii K, Hayashi N, Naito M, Kashiwabara K, Yamashita T, Umeda M, Mukai H, Ota Y. Oral care evaluation to prevent oral mucositis in estrogen receptor positive metastatic breast cancer patients treated with everolimus (Oral Care-BC): A randomized controlled phase III trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-11-01.
Collapse
Affiliation(s)
- N Niikura
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - K Nakatukasa
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - T Amamiya
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - K-i Watanabe
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - H Hata
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - Y Kikawa
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - N Taniike
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - T Yamanaka
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - S Mitsunaga
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - K Nakagami
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - M Adachi
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - N Kondo
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - K Horii
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - N Hayashi
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - M Naito
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - K Kashiwabara
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - T Yamashita
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - M Umeda
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - H Mukai
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - Y Ota
- Tokai University School of Medicine, Isehara, Kanagawa, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Shizuoka General Hospital, Shizuoka, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Nagoya City University Hospital, Nagoya, Aichi, Japan; St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; School of Public Health, the University of Tokyo, Bunkyo-ku, Tokyo, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| |
Collapse
|
29
|
Adachi M, Hasegawa T, Tanaka Y, Asakura Y, Hanakawa J, Muroya K. Spontaneous virilization around puberty in NR5A1-related 46,XY sex reversal: additional case and a literature review. Endocr J 2018; 65:1187-1192. [PMID: 30224582 DOI: 10.1507/endocrj.ej18-0218] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
A heterozygous NR5A1 mutation is one of the most frequent causes of 46,XY DSD (disorders of sex development). We here reported a NR5A1-related 46,XY DSD patient, who first received endocrinological attention at 10 years of age for clitoromegaly. The patient had been reared as a girl, and no signs of virilization had been detected before. On examination, her clitoris was 35 mm long and 10 mm wide, with Tanner 3° pubic hair. Urogenital sinus and labial fusion was absent, while her uterus was found to be severely hypoplastic. Her basal testosterone level was 94.8 ng/dL, suggesting the presence of functioning Leydig cells. Gonadal histology revealed bilateral dysplastic testes consisting of mostly Sertoli cell-only tubules and Leydig cell hyperplasia. Novel heterozygous Arg313Leu substitution in NR5A1 was identified in the patient. Literature search confirmed twelve other cases of this scenario, namely, severe under-virilization in utero followed by spontaneous virilization around puberty in NR5A1-related 46,XY DSD. Of interest, Leydig cell hyperplasia was documented in 6 out of 9 patients for whom testicular histology was available. To keep in mind about the possible restoration of Leydig cell function around puberty, even in patients without discernible in utero androgen effect, may be of clinical significance, because it will give a great impact on the judgement about sex assignment.
Collapse
Affiliation(s)
- Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama 232-8555, Japan
| | - Tomonobu Hasegawa
- Department of Pediatrics, Keio University School of Medicine, Tokyo 160-8582, Japan
| | - Yukichi Tanaka
- Division of Diagnostic Pathology, Kanagawa Children's Medical Center, Yokohama 232-8555, Japan
| | - Yumi Asakura
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama 232-8555, Japan
| | - Junko Hanakawa
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama 232-8555, Japan
| | - Koji Muroya
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama 232-8555, Japan
| |
Collapse
|
30
|
Kisu I, Banno K, Matoba Y, Adachi M, Aoki D. Current Status of Uterus Transplantation and Approaches for Future Clinical Application in Japan. Transplant Proc 2018; 50:2783-2788. [DOI: 10.1016/j.transproceed.2018.02.198] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2018] [Accepted: 02/26/2018] [Indexed: 01/28/2023]
|
31
|
Ishii T, Adachi M, Takasawa K, Okada S, Kamasaki H, Kubota T, Kobayashi H, Sawada H, Nagasaki K, Numakura C, Harada S, Minamitani K, Sugihara S, Tajima T. Incidence and Characteristics of Adrenal Crisis in Children Younger than 7 Years with 21-Hydroxylase Deficiency: A Nationwide Survey in Japan. Horm Res Paediatr 2018; 89:166-171. [PMID: 29455197 DOI: 10.1159/000486393] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/25/2017] [Accepted: 12/18/2017] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND/AIMS We aimed to evaluate the incidence and characteristics of adrenal crisis in Japanese children with 21-hydroxylase deficiency (21-OHD). METHODS We conducted a retrospective nationwide survey for the councilors of the Japanese Society for Pediatric Endocrinology (JSPE) regarding adrenal crisis in children under 7 years with 21-OHD, admitted to hospitals from 2011 through 2016. We defined adrenal crisis as the acute impairment of general health due to glucocorticoid deficiency with at least two of symptoms, signs, or biochemical abnormalities. RESULTS The councilors of the JSPE in 83 institutions responded to this survey (response rate, 60.1%). Data analyses of 378 patients with 1,101.4 person-years (PYs) revealed that 67 patients (17.7%) experienced at least 1 episode of hospital admission for adrenal crisis at the median age of 2 years. The incidence of adrenal crisis was calculated as 10.9 per 100 PYs (95% confidence interval [CI] 9.6-12.2). Infections were the most common precipitating factors, while no factor was observed in 12.5%. Hypoglycemia occurred concomitantly in 27.4%. One patient died from severe hypoglycemia, resulting in a mortality rate of 0.09 per 100 PYs (95% CI 0.0-0.2). CONCLUSION Adrenal crisis is not rare and can be accompanied by disastrous hypoglycemia in children with 21-OHD.
Collapse
Affiliation(s)
- Tomohiro Ishii
- The Committee on Mass Screening, Japanese Society for Pediatric Endocrinology, Kyoto, Japan.,Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
| | - Masanori Adachi
- The Committee on Mass Screening, Japanese Society for Pediatric Endocrinology, Kyoto, Japan.,Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Kei Takasawa
- The Committee on Mass Screening, Japanese Society for Pediatric Endocrinology, Kyoto, Japan.,Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan
| | - Satoshi Okada
- The Committee on Mass Screening, Japanese Society for Pediatric Endocrinology, Kyoto, Japan.,Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan
| | - Hotaka Kamasaki
- The Committee on Mass Screening, Japanese Society for Pediatric Endocrinology, Kyoto, Japan.,Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Takuo Kubota
- The Committee on Mass Screening, Japanese Society for Pediatric Endocrinology, Kyoto, Japan.,Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Hironori Kobayashi
- The Committee on Mass Screening, Japanese Society for Pediatric Endocrinology, Kyoto, Japan.,Department of Pediatrics, Shimane University Faculty of Medicine, Shimane, Japan
| | - Hirotake Sawada
- The Committee on Mass Screening, Japanese Society for Pediatric Endocrinology, Kyoto, Japan.,Department of Reproductive and Developmental Medicine, University of Miyazaki, Miyazaki, Japan
| | - Keisuke Nagasaki
- The Committee on Mass Screening, Japanese Society for Pediatric Endocrinology, Kyoto, Japan.,Division of Pediatrics, Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Chikahiko Numakura
- The Committee on Mass Screening, Japanese Society for Pediatric Endocrinology, Kyoto, Japan.,Department of Pediatrics, Yamagata University School of Medicine, Yamagata, Japan
| | - Shohei Harada
- The Committee on Mass Screening, Japanese Society for Pediatric Endocrinology, Kyoto, Japan.,Department of Child Studies, Seitoku University, Matsudo, Japan
| | - Kanshi Minamitani
- The Committee on Mass Screening, Japanese Society for Pediatric Endocrinology, Kyoto, Japan.,Department of Pediatrics, Teikyo University Chiba Medical Center, Chiba, Japan
| | - Shigetaka Sugihara
- The Committee on Mass Screening, Japanese Society for Pediatric Endocrinology, Kyoto, Japan.,Department of Pediatrics, Tokyo Women's Medical University Medical Center East, Tokyo, Japan
| | - Toshihiro Tajima
- The Committee on Mass Screening, Japanese Society for Pediatric Endocrinology, Kyoto, Japan.,Department of Pediatrics, Jichi Medical University Tochigi Childrens Medical Center, Shimotsuke, Japan
| |
Collapse
|
32
|
Cheong HI, Yoo HW, Adachi M, Tanaka H, Fujiwara I, Hasegawa Y, Harada D, Sugimoto M, Okada Y, Kato M, Shimazaki R, Ozono K, Seino Y. First-in-Asian Phase I Study of the Anti-Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X-linked Hypophosphatemia. JBMR Plus 2018; 3:e10074. [PMID: 30828689 PMCID: PMC6383703 DOI: 10.1002/jbm4.10074] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Revised: 08/03/2018] [Accepted: 08/05/2018] [Indexed: 12/26/2022] Open
Abstract
X‐linked hypophosphatemia (XLH) is a disease caused by abnormally elevated FGF23 levels, which cause persistent hypophosphatemia accompanied by subsequent reduction in bone mineralization that presents as rickets or osteomalacia. Burosumab is a fully human monoclonal antibody targeting FGF23 that is under development for the treatment of FGF23‐related hypophosphatemia including XLH. The safety, tolerability, and proof of concept of burosumab have been evaluated in patients with XLH in previous studies conducted in countries outside of Asia. The objective of this study was to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and expression of anti‐drug antibodies in Japanese and Korean adults with XLH. This was a multicenter, sequential dose‐escalation, open‐label, single‐dose study. This study began with cohort 1 (s.c. dose of burosumab 0.3 mg/kg), after which the dose was escalated sequentially in cohort 2 (s.c. dose of burosumab 0.6 mg/kg) and cohort 3 (s.c. dose of burosumab 1.0 mg/kg). The PK of burosumab were linear within the dose range of 0.3 to 1.0 mg/kg. The PD effects such as serum phosphorus concentration, serum 1,25[OH]2D3 concentration, and ratio of tubular maximum reabsorption rate of phosphate to glomerular filtration rate (TmP/GFR) were elevated after a single s.c. administration. The area under the receiver‐operating characteristic curve from 0 to t (AUC0–t) values calculated using the change from baseline values of serum phosphorus, serum 1,25(OH)2D3, and TmP/GFR were correlated with the AUC0–t of burosumab. Furthermore, no serious adverse events (AEs), deaths, remarkable increase or decrease in the corrected calcium or intact PTH levels, or signs of nephrocalcinosis or its worsening were observed after treatment. Some AEs and drug‐related AEs were observed; however, there were no clinically meaningful tendencies. The positive effects and acceptable safety profile seen in this study are encouraging for Japanese and Korean patients with XLH. © 2018 The Authors JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
Collapse
Affiliation(s)
- Hae Il Cheong
- Department of Pediatrics Seoul National University Children's Hospital Seoul Republic of Korea
| | - Han-Wook Yoo
- Department of Pediatrics Asan Medical Center Seoul Republic of Korea
| | - Masanori Adachi
- Department of Endocrinology and Metabolism Kanagawa Children's Medical Center Kanagawa Japan
| | - Hiroyuki Tanaka
- Department of Pediatrics Okayama Saiseikai General Hospital Okayama Japan
| | - Ikuma Fujiwara
- Department of Pediatric Endocrinology and Environmental Medicine Tohoku University Graduate School of Medicine Miyagi Japan
| | - Yukihiro Hasegawa
- Division of Endocrinology and Metabolism Tokyo Metropolitan Children's Medical Center Tokyo Japan
| | - Daisuke Harada
- Department of Pediatrics Osaka Hospital Japan Community Healthcare Organization (JCHO) Osaka Japan
| | | | | | | | | | - Keiichi Ozono
- Department of Pediatrics Osaka University Graduate School of Medicine Osaka Japan
| | - Yoshiki Seino
- Department of Pediatrics Osaka Hospital Japan Community Healthcare Organization (JCHO) Osaka Japan
| |
Collapse
|
33
|
Iijima H, Iwano R, Tanaka Y, Muroya K, Fukuda T, Sugie H, Kurosawa K, Adachi M. Analysis of GBE1 mutations via protein expression studies in glycogen storage disease type IV: A report on a non-progressive form with a literature review. Mol Genet Metab Rep 2018; 17:31-37. [PMID: 30228975 PMCID: PMC6140619 DOI: 10.1016/j.ymgmr.2018.09.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2018] [Revised: 09/06/2018] [Accepted: 09/06/2018] [Indexed: 11/26/2022] Open
Abstract
Background Glycogen storage disease type IV (GSD IV), caused by GBE1 mutations, has a quite wide phenotypic variation. While the classic hepatic form and the perinatal/neonatal neuromuscular forms result in early mortality, milder manifestations include non-progressive form (NP-GSD IV) and adult polyglucosan body disease (APBD). Thus far, only one clinical case of a patient with compound heterozygous mutations has been reported for the molecular analysis of NP-GSD IV. This study aimed to elucidate the molecular basis in a NP-GSD IV patient via protein expression analysis and to obtain a clearer genotype-phenotype relationship in GSD IV. Case presentation A Japanese boy presented hepatosplenomegaly at 2 years of age. Developmental delay, neurological symptoms, and cardiac dysfunction were not apparent. Observation of hepatocytes with periodic acid-Schiff-positive materials resistant to diastase, coupled with resolution of hepatosplenomegaly at 8 years of age, yielded a diagnosis of NP-GSD IV. Glycogen branching enzyme activity was decreased in erythrocytes. At 13 years of age, he developed epilepsy, which was successfully controlled by carbamazepine. Molecular analysis In this study, we identified compound heterozygous GBE1 mutations (p.Gln46Pro and p.Glu609Lys). The branching activities of the mutant proteins expressed using E. coli were examined in a reaction with starch. The result showed that both mutants had approximately 50% activity of the wild type protein. Conclusion This is the second clinical report of a NP-GSD IV patient with a definite molecular elucidation. Based on the clinical and genotypic overlapping between NP-GSD IV and APBD, we suggest both are in a continuum.
Collapse
Affiliation(s)
- Hiroyuki Iijima
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Mutsukawa 2-138-4, Minami-ku, Yokohama 232-8555, Japan
| | - Reiko Iwano
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Mutsukawa 2-138-4, Minami-ku, Yokohama 232-8555, Japan
| | - Yukichi Tanaka
- Department of Pathology, Kanagawa Children's Medical Center, Mutsukawa 2-138-4, Minami-ku, Yokohama 232-8555, Japan
| | - Koji Muroya
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Mutsukawa 2-138-4, Minami-ku, Yokohama 232-8555, Japan
| | - Tokiko Fukuda
- Department of Pediatrics, Hamamatsu University School of Medicine, Handayama, 1-20-1 Higashi-ku, Hamamatsu 431-3192, Japan
| | - Hideo Sugie
- Faculty of Health and Medical Sciences, Tokoha University, Sena, 1-22-1 Aoi-ku, Shizuoka 420-0911, Japan
| | - Kenji Kurosawa
- Division of Medical Genetics, Kanagawa Children's Medical Center, Mutsukawa 2-138-4, Minami-ku, Yokohama 232-8555, Japan
| | - Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Mutsukawa 2-138-4, Minami-ku, Yokohama 232-8555, Japan
| |
Collapse
|
34
|
Adachi M, Takahashi K, Yuge K, Nishikawa M, Miki H, Uyama M. Treatment with Bifemelane for Optic Nerve Damage following High Intraocular Pressure in Rat Eyes. Eur J Ophthalmol 2018; 6:415-20. [PMID: 8997585 DOI: 10.1177/112067219600600413] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
This study found that pretreatment with 4-(o-benzylphenoxy)-N- methylbuty-lamine hydrochloride (bifemelane hydrochloride, Celeport) reduced ischemia-reperfusion injury in rat eyes. Bifemelane (25 mg/kg) was injected intraperitoneally 30 minutes before an ischemic insult, then acute ischemia of the retina and optic disc was induced by increasing intraocular pressure to 110 mmHg for 45 minutes. After one week, the axonal count of the optic nerve was investigated using electron microscopy. The control group consisted of vehicle-treated eyes which received normal saline. The axon count was 93.4 +/- 7.9 for the bifemelane treated group, and 79.2 +/- 6.4 for the controls. The axon count in the treated group was significantly higher. These results suggest that bifemelane, which prevents cerebral nerve cell damage from ischemia, can reduce ischemic retinal nerve cell injury.
Collapse
Affiliation(s)
- M Adachi
- Department of Ophthalmology, Kansai Medical University, Osaka, Japan
| | | | | | | | | | | |
Collapse
|
35
|
Tomotaki S, Naramura T, Hanakawa J, Toyoshima K, Muroya K, Adachi M. Fluctuation of blood glucose levels in an infant with an ileostomy on continuous glucose monitoring: A case report. Clin Pediatr Endocrinol 2018; 27:39-43. [PMID: 29403155 PMCID: PMC5792820 DOI: 10.1297/cpe.27.39] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/14/2017] [Accepted: 08/29/2017] [Indexed: 11/05/2022] Open
Abstract
Infants with an ileostomy can be at high risk of hypoglycemia because of inadequate
nutritional intake; however, there are no reports investigating blood glucose (BG) in
infants with ileostomy. We experienced a case of an extremely low birth weight infant who
was born at 24 wk of gestation and weighted 623 g. He received an ileostomy because of an
intestinal perforation. After the ileostomy, he had recurrent hypoglycemia. Continuous
glucose monitoring showed fluctuation of BG levels (postprandial BG elevations and
subsequent declines) and non-fasting hypoglycemia, which were undetectable with
intermittent fasting BG measurement. The fluctuation of BG levels and non-fasting
hypoglycemia improved after closure of the ileostomy. Patients with ileostomy may present
with hypoglycemia that is undetectable with intermittent fasting BG measurement. In this
case, continuous glucose monitoring was very useful for detecting fluctuation of BG levels
and hypoglycemic episodes. Therefore, we recommend that continuous glucose monitoring be
performed in infants with an ileostomy to confirm whether they have hypoglycemia or a
fluctuation in BG levels. Further studies on the postprandial dynamics of various hormones
in infants with ileostomy are required.
Collapse
Affiliation(s)
- Seiichi Tomotaki
- Department of Neonatology, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Tetsuo Naramura
- Department of Neonatology, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Junko Hanakawa
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Katsuaki Toyoshima
- Department of Neonatology, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Koji Muroya
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| |
Collapse
|
36
|
Abe K, Narumi S, Suwanai AS, Adachi M, Muroya K, Asakura Y, Nagasaki K, Abe T, Hasegawa T. Association between monoallelic TSHR mutations and congenital hypothyroidism: a statistical approach. Eur J Endocrinol 2018; 178:137-144. [PMID: 29092890 DOI: 10.1530/eje-16-1049] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/20/2016] [Revised: 09/30/2017] [Accepted: 11/01/2017] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Biallelic TSHR mutations cause congenital hypothyroidism (CH). Serum TSH levels of monoallelic mutation carriers range from normal to mildly elevated, and thus the size of its effect remains unclear. The objectives were to examine the association between monoallelic TSHR mutations and positivity at newborn screening (NBS) for CH, and to test whether the association was modified by another genetic factor. SUBJECTS AND METHODS We enrolled 395 patients that had a positive result in NBS and sequenced TSHR. Monoallelic TSHR mutation carriers were further sequenced for DUOX2. Molecular functions of the mutations were verified in vitro. The frequency of the mutations in the study subjects was compared with a theoretical value in the Japanese general population. Odds ratio (OR) for NBS positivity associated with the mutation was calculated. Using Bayes' theorem, we estimated a posterior probability of NBS positivity given the mutation. RESULTS Twenty-six monoallelic TSHR mutation carriers were found. Four out of the 26 also had a monoallelic DUOX2 mutation (double heterozygotes). The frequencies of monoallelic TSHR mutation carriers (6.6%) and double heterozygotes (1.0%) were significantly higher than those in the general population (0.58% and 0.0087%, respectively). OR for NBS positivity of having a monoallelic TSHR mutation or being a double heterozygote was 12.0 or 117.9, respectively. Posterior probability of NBS positivity was 0.38% in monoallelic TSHR mutation carriers and 3.8% in double heterozygotes. CONCLUSIONS Monoallelic TSHR mutations are significantly associated with NBS positivity, and the association is further strengthened by the coexistence of monoallelic DUOX2 mutations.
Collapse
Affiliation(s)
- Kiyomi Abe
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
| | - Satoshi Narumi
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan
| | - Ayuko S Suwanai
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
| | - Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Koji Muroya
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Yumi Asakura
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Keisuke Nagasaki
- Division of Pediatrics, Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medicine and Dental Sciences, Niigata, Japan
| | - Takayuki Abe
- Center for Clinical Research, Keio University School of Medicine, Tokyo, Japan
| | - Tomonobu Hasegawa
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
37
|
Adachi M, Soneda A. Unnoticed maternal Graves' disease revealed by the baby's low free thyroxine in newborn screening: an underestimated condition supporting thyroid disease screening among pregnant women. J Endocrinol Invest 2018; 41:143-144. [PMID: 29094333 DOI: 10.1007/s40618-017-0777-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/16/2017] [Accepted: 10/09/2017] [Indexed: 10/18/2022]
Affiliation(s)
- M Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, 232-8555, Japan.
| | - A Soneda
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, 232-8555, Japan
| |
Collapse
|
38
|
Bousquet J, Farrell J, Crooks G, Hellings P, Bel EH, Bewick M, Chavannes NH, de Sousa JC, Cruz AA, Haahtela T, Joos G, Khaltaev N, Malva J, Muraro A, Nogues M, Palkonen S, Pedersen S, Robalo-Cordeiro C, Samolinski B, Strandberg T, Valiulis A, Yorgancioglu A, Zuberbier T, Bedbrook A, Aberer W, Adachi M, Agusti A, Akdis CA, Akdis M, Ankri J, Alonso A, Annesi-Maesano I, Ansotegui IJ, Anto JM, Arnavielhe S, Arshad H, Bai C, Baiardini I, Bachert C, Baigenzhin AK, Barbara C, Bateman ED, Beghé B, Kheder AB, Bennoor KS, Benson M, Bergmann KC, Bieber T, Bindslev-Jensen C, Bjermer L, Blain H, Blasi F, Boner AL, Bonini M, Bonini S, Bosnic-Anticevitch S, Boulet LP, Bourret R, Bousquet PJ, Braido F, Briggs AH, Brightling CE, Brozek J, Buhl R, Burney PG, Bush A, Caballero-Fonseca F, Caimmi D, Calderon MA, Calverley PM, Camargos PAM, Canonica GW, Camuzat T, Carlsen KH, Carr W, Carriazo A, Casale T, Cepeda Sarabia AM, Chatzi L, Chen YZ, Chiron R, Chkhartishvili E, Chuchalin AG, Chung KF, Ciprandi G, Cirule I, Cox L, Costa DJ, Custovic A, Dahl R, Dahlen SE, Darsow U, De Carlo G, De Blay F, Dedeu T, Deleanu D, De Manuel Keenoy E, Demoly P, Denburg JA, Devillier P, Didier A, Dinh-Xuan AT, Djukanovic R, Dokic D, Douagui H, Dray G, Dubakiene R, Durham SR, Dykewicz MS, El-Gamal Y, Emuzyte R, Fabbri LM, Fletcher M, Fiocchi A, Fink Wagner A, Fonseca J, Fokkens WJ, Forastiere F, Frith P, Gaga M, Gamkrelidze A, Garces J, Garcia-Aymerich J, Gemicioğlu B, Gereda JE, González Diaz S, Gotua M, Grisle I, Grouse L, Gutter Z, Guzmán MA, Heaney LG, Hellquist-Dahl B, Henderson D, Hendry A, Heinrich J, Heve D, Horak F, Hourihane JOB, Howarth P, Humbert M, Hyland ME, Illario M, Ivancevich JC, Jardim JR, Jares EJ, Jeandel C, Jenkins C, Johnston SL, Jonquet O, Julge K, Jung KS, Just J, Kaidashev I, Khaitov MR, Kalayci O, Kalyoncu AF, Keil T, Keith PK, Klimek L, Koffi N’Goran B, Kolek V, Koppelman GH, Kowalski ML, Kull I, Kuna P, Kvedariene V, Lambrecht B, Lau S, Larenas-Linnemann D, Laune D, Le LTT, Lieberman P, Lipworth B, Li J, Lodrup Carlsen K, Louis R, MacNee W, Magard Y, Magnan A, Mahboub B, Mair A, Majer I, Makela MJ, Manning P, Mara S, Marshall GD, Masjedi MR, Matignon P, Maurer M, Mavale-Manuel S, Melén E, Melo-Gomes E, Meltzer EO, Menzies-Gow A, Merk H, Michel JP, Miculinic N, Mihaltan F, Milenkovic B, Mohammad GMY, Molimard M, Momas I, Montilla-Santana A, Morais-Almeida M, Morgan M, Mösges R, Mullol J, Nafti S, Namazova-Baranova L, Naclerio R, Neou A, Neffen H, Nekam K, Niggemann B, Ninot G, Nyembue TD, O’Hehir RE, Ohta K, Okamoto Y, Okubo K, Ouedraogo S, Paggiaro P, Pali-Schöll I, Panzner P, Papadopoulos N, Papi A, Park HS, Passalacqua G, Pavord I, Pawankar R, Pengelly R, Pfaar O, Picard R, Pigearias B, Pin I, Plavec D, Poethig D, Pohl W, Popov TA, Portejoie F, Potter P, Postma D, Price D, Rabe KF, Raciborski F, Radier Pontal F, Repka-Ramirez S, Reitamo S, Rennard S, Rodenas F, Roberts J, Roca J, Rodriguez Mañas L, Rolland C, Roman Rodriguez M, Romano A, Rosado-Pinto J, Rosario N, Rosenwasser L, Rottem M, Ryan D, Sanchez-Borges M, Scadding GK, Schunemann HJ, Serrano E, Schmid-Grendelmeier P, Schulz H, Sheikh A, Shields M, Siafakas N, Sibille Y, Similowski T, Simons FER, Sisul JC, Skrindo I, Smit HA, Solé D, Sooronbaev T, Spranger O, Stelmach R, Sterk PJ, Sunyer J, Thijs C, To T, Todo-Bom A, Triggiani M, Valenta R, Valero AL, Valia E, Valovirta E, Van Ganse E, van Hage M, Vandenplas O, Vasankari T, Vellas B, Vestbo J, Vezzani G, Vichyanond P, Viegi G, Vogelmeier C, Vontetsianos T, Wagenmann M, Wallaert B, Walker S, Wang DY, Wahn U, Wickman M, Williams DM, Williams S, Wright J, Yawn BP, Yiallouros PK, Yusuf OM, Zaidi A, Zar HJ, Zernotti ME, Zhang L, Zhong N, Zidarn M, Mercier J. Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). Clin Transl Allergy 2017; 7:5. [PMID: 28239450 PMCID: PMC5319069 DOI: 10.1186/s13601-016-0135-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Accepted: 11/29/2016] [Indexed: 11/10/2022] Open
|
39
|
Hattori A, Katoh-Fukui Y, Nakamura A, Matsubara K, Kamimaki T, Tanaka H, Dateki S, Adachi M, Muroya K, Yoshida S, Ida S, Mitani M, Nagasaki K, Ogata T, Suzuki E, Hata K, Nakabayashi K, Matsubara Y, Narumi S, Tanaka T, Fukami M. Next generation sequencing-based mutation screening of 86 patients with idiopathic short stature. Endocr J 2017; 64:947-954. [PMID: 28768959 DOI: 10.1507/endocrj.ej17-0150] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Although mutations in ACAN, FGFR3, NPR2, and SHOX typically lead to skeletal dysplasia, and mutations in GHRHR, GH1, GHR, STAT5B, IGF1, IGFALS, and IGF1R usually underlie hormonal defects of the growth hormone (GH)-insulin-like growth factor 1 (IGF1) axis, such mutations have also been identified in patients with idiopathic short stature (ISS). Of these, SHOX abnormalities are known to account for a certain percentage of ISS cases, whereas the frequency of mutations in the other 10 genes in ISS cohorts remains unknown. Here, we performed next-generation sequencing-based mutation screening of the 10 genes in 86 unrelated Japanese ISS patients without SHOX abnormalities. We searched for rare protein-altering variants. The functional significance of the identified variants was assessed by in silico analyses. Consequently, we identified 18 heterozygous rare variants in 19 patients, including four probable damaging variants in ACAN, six pathogenicity-unknown variants in FGFR3, GHRHR, GHR, and IGFALS, and eight possible benign variants. Pathogenic variants in NPR2, GH1, and IGF1 were absent from our cohort. Unlike previously reported patients with ACAN mutations, our four patients with ACAN variants manifested non-specific short stature with age-appropriate or mildly delayed bone ages, and had parents of normal stature. These results indicate that ACAN mutations can underlie ISS without characteristic skeletal features, and that such mutations are possibly associated with de novo occurrence or low penetrance. In addition, our data imply that mutations in FGFR3, NPR2, and GH-IGF1 axis genes play only limited roles in the etiology of ISS.
Collapse
MESH Headings
- Aggrecans/chemistry
- Aggrecans/genetics
- Aggrecans/metabolism
- Amino Acid Substitution
- Carrier Proteins/chemistry
- Carrier Proteins/genetics
- Carrier Proteins/metabolism
- Child
- Child, Preschool
- Cohort Studies
- Computational Biology
- Databases, Genetic
- Expert Systems
- Female
- Genetic Association Studies
- Genetic Predisposition to Disease
- Genetic Testing
- Glycoproteins/chemistry
- Glycoproteins/genetics
- Glycoproteins/metabolism
- Growth Disorders/blood
- Growth Disorders/genetics
- Growth Disorders/metabolism
- Growth Disorders/physiopathology
- Heterozygote
- High-Throughput Nucleotide Sequencing
- Humans
- Japan
- Male
- Mutation
- Receptor, Fibroblast Growth Factor, Type 3/chemistry
- Receptor, Fibroblast Growth Factor, Type 3/genetics
- Receptor, Fibroblast Growth Factor, Type 3/metabolism
- Receptor, IGF Type 1
- Receptors, Neuropeptide/chemistry
- Receptors, Neuropeptide/genetics
- Receptors, Neuropeptide/metabolism
- Receptors, Pituitary Hormone-Regulating Hormone/chemistry
- Receptors, Pituitary Hormone-Regulating Hormone/genetics
- Receptors, Pituitary Hormone-Regulating Hormone/metabolism
- Receptors, Somatomedin/chemistry
- Receptors, Somatomedin/genetics
- Receptors, Somatomedin/metabolism
- STAT5 Transcription Factor/chemistry
- STAT5 Transcription Factor/genetics
- STAT5 Transcription Factor/metabolism
Collapse
Affiliation(s)
- Atsushi Hattori
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan
- Department of Advanced Pediatric Medicine, Tohoku University School of Medicine, Tokyo 157-8535, Japan
| | - Yuko Katoh-Fukui
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan
| | - Akie Nakamura
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan
| | - Keiko Matsubara
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan
| | - Tsutomu Kamimaki
- Department of Pediatrics, Shizuoka City Shimizu Hospital, Shizuoka 424-8636, Japan
| | - Hiroyuki Tanaka
- Department of Pediatrics, Okayama Saiseikai General Hospital, Okayama 700-8511, Japan
| | - Sumito Dateki
- Department of Pediatrics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan
| | - Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama 232-8555, Japan
| | - Koji Muroya
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama 232-8555, Japan
| | - Shinobu Yoshida
- Department of Pediatrics, Omihachiman Community Medical Center, Omihachiman 523-0082, Japan
| | - Shinobu Ida
- Department of Gastroenterology and Endocrinology, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi 594-1101, Japan
| | - Marie Mitani
- Department of Pediatrics, Shizuoka City Shimizu Hospital, Shizuoka 424-8636, Japan
| | - Keisuke Nagasaki
- Division of Pediatrics, Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8520, Japan
| | - Tsutomu Ogata
- Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
| | - Erina Suzuki
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan
| | - Kenichiro Hata
- Department of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan
| | - Kazuhiko Nakabayashi
- Department of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan
| | - Yoichi Matsubara
- Department of Advanced Pediatric Medicine, Tohoku University School of Medicine, Tokyo 157-8535, Japan
- Institute director, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan
| | - Satoshi Narumi
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan
| | | | - Maki Fukami
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan
| |
Collapse
|
40
|
Takeuchi K, Furuta M, Okabe Y, Suma S, Takeshita T, Akifusa S, Adachi M, Kinoshita T, Kikutani T, Yamashita Y. Swallowing disorders and 1-year functional decline in community-dwelling older adults receiving home care. J Oral Rehabil 2017; 44:982-987. [DOI: 10.1111/joor.12577] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/26/2017] [Indexed: 11/30/2022]
Affiliation(s)
- K. Takeuchi
- Section of Preventive and Public Health Dentistry; Division of Oral Health, Growth and Development; Faculty of Dental Science; Kyushu University; Fukuoka Japan
| | - M. Furuta
- Section of Preventive and Public Health Dentistry; Division of Oral Health, Growth and Development; Faculty of Dental Science; Kyushu University; Fukuoka Japan
| | - Y. Okabe
- Section of Preventive and Public Health Dentistry; Division of Oral Health, Growth and Development; Faculty of Dental Science; Kyushu University; Fukuoka Japan
| | - S. Suma
- Section of Preventive and Public Health Dentistry; Division of Oral Health, Growth and Development; Faculty of Dental Science; Kyushu University; Fukuoka Japan
| | - T. Takeshita
- Section of Preventive and Public Health Dentistry; Division of Oral Health, Growth and Development; Faculty of Dental Science; Kyushu University; Fukuoka Japan
- OBT Research Center; Faculty of Dental Science; Kyushu University; Fukuoka Japan
| | - S. Akifusa
- Department of Health Management; School of Oral Health Science; Kyushu Dental College; Kitakyushu Japan
| | - M. Adachi
- Itoshima Dental Association; Itoshima Japan
| | | | - T. Kikutani
- Rehabilitation Clinic for Speech and Swallowing Disorders; The Nippon Dental University Hospital; Tokyo Japan
| | - Y. Yamashita
- Section of Preventive and Public Health Dentistry; Division of Oral Health, Growth and Development; Faculty of Dental Science; Kyushu University; Fukuoka Japan
| |
Collapse
|
41
|
Sato T, Adachi M, Nakamura K, Zushi M, Goto K, Murakami T, Ishiguro K, Shichiji M, Saito K, Ikai T, Osawa M, Kondo I, Nagata S, Ishigaki K. The gross motor function measure is valid for Fukuyama congenital muscular dystrophy. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
42
|
Nagasaki K, Kubota T, Kobayashi H, Sawada H, Numakura C, Harada S, Takasawa K, Minamitani K, Ishii T, Okada S, Kamasaki H, Sugihara S, Adachi M, Tajima T. Clinical characteristics of septo-optic dysplasia accompanied by congenital central hypothyroidism in Japan. Clin Pediatr Endocrinol 2017; 26:207-213. [PMID: 29026269 PMCID: PMC5627221 DOI: 10.1297/cpe.26.207] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/04/2017] [Accepted: 05/06/2017] [Indexed: 11/05/2022] Open
Abstract
Septo-optic dysplasia (SOD) is a congenital anomaly in which agenesis of the septum pellucidum and optic nerve hypoplasia are accompanied by hypopituitarism. Typically, the symptoms develop in 3 organs, the brain, eyes, and pituitary, and approximately one third of the patients present with all of the three cardinal features. The diagnostic criteria for SOD were established in Japan in 2015. The purpose of this study is to review clinical features regarding SOD patients with hypopituitarism in Japan. In this study, 21 patients with SOD were identified by a questionnaire survey for congenital central hypothyroidism. All 3 symptoms of SOD, agenesis of the septum pellucidum, optic nerve hypoplasia, and endocrine abnormalities, were noted in 8 of the 21 patients. Various combinations of pituitary hormone deficiencies were observed in patients with SOD, although SOD is a rare, heterogeneous, and phenotypically variable disorder, some patients develop hypoglycemia and convulsions after birth, and early intervention with hormone replacement is necessary in severe cases. In addition, 14 cases were complicated by both developmental delay and epilepsy, and 16 cases involved eye abnormalities. Therefore, in addition to an early endocrinological diagnosis and hormone replacement, consultation with both pediatric neurologists and pediatric ophthalmologists is necessary.
Collapse
Affiliation(s)
- Keisuke Nagasaki
- Division of Pediatrics, Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- The Committee on Mass Screening of the Japanese Society for Pediatric Endocrinology
| | - Takuo Kubota
- Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan
- The Committee on Mass Screening of the Japanese Society for Pediatric Endocrinology
| | - Hironori Kobayashi
- Department of Pediatrics, Shimane University Faculty of Medicine, Shimane, Japan
- The Committee on Mass Screening of the Japanese Society for Pediatric Endocrinology
| | - Hirotake Sawada
- Department of Reproductive and Developmental Medicine, University of Miyazaki, Miyazaki, Japan
- The Committee on Mass Screening of the Japanese Society for Pediatric Endocrinology
| | - Chikahiko Numakura
- Department of Pediatrics, Yamagata University School of Medicine, Yamagata, Japan
- The Committee on Mass Screening of the Japanese Society for Pediatric Endocrinology
| | - Shohei Harada
- Faculty of Child Studies, Seitoku University, Chiba, Japan
- The Committee on Mass Screening of the Japanese Society for Pediatric Endocrinology
| | - Kei Takasawa
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan
- The Committee on Mass Screening of the Japanese Society for Pediatric Endocrinology
| | - Kanshi Minamitani
- Department of Pediatrics, Teikyo University Chiba Medical Center, Chiba, Japan
- The Committee on Mass Screening of the Japanese Society for Pediatric Endocrinology
| | - Tomohiro Ishii
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
- The Committee on Mass Screening of the Japanese Society for Pediatric Endocrinology
| | - Satoshi Okada
- Department of Pediatrics, Hiroshima University Graduate School of Biomedical & Health Sciences, Hiroshima, Japan
- The Committee on Mass Screening of the Japanese Society for Pediatric Endocrinology
| | - Hotaka Kamasaki
- Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, Japan
- The Committee on Mass Screening of the Japanese Society for Pediatric Endocrinology
| | - Shigetaka Sugihara
- Department of Pediatrics, Tokyo Women's Medical University Medical Center East, Tokyo, Japan
- The Committee on Mass Screening of the Japanese Society for Pediatric Endocrinology
| | - Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
- The Committee on Mass Screening of the Japanese Society for Pediatric Endocrinology
| | - Toshihiro Tajima
- Department of Pediatrics, Jichi Children's Medical Center Tochigi, Tochigi, Japan
- The Committee on Mass Screening of the Japanese Society for Pediatric Endocrinology
| |
Collapse
|
43
|
Yorifuji T, Horikawa R, Hasegawa T, Adachi M, Soneda S, Minagawa M, Ida S, Yonekura T, Kinoshita Y, Kanamori Y, Kitagawa H, Shinkai M, Sasaki H, Nio M. Clinical practice guidelines for congenital hyperinsulinism. Clin Pediatr Endocrinol 2017; 26:127-152. [PMID: 28804205 PMCID: PMC5537210 DOI: 10.1297/cpe.26.127] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/21/2017] [Accepted: 03/08/2017] [Indexed: 12/11/2022] Open
Abstract
Congenital hyperinsulinism is a rare condition, and following recent advances in
diagnosis and treatment, it was considered necessary to formulate evidence-based clinical
practice guidelines reflecting the most recent progress, to guide the practice of
neonatologists, pediatric endocrinologists, general pediatricians, and pediatric surgeons.
These guidelines cover a range of aspects, including general features of congenital
hyperinsulinism, diagnostic criteria and tools for diagnosis, first- and second-line
medical treatment, criteria for and details of surgical treatment, and future
perspectives. These guidelines were generated as a collaborative effort between The
Japanese Society for Pediatric Endocrinology and The Japanese Society of Pediatric
Surgeons, and followed the official procedures of guideline generation to identify
important clinical questions, perform a systematic literature review (April 2016), assess
the evidence level of each paper, formulate the guidelines, and obtain public
comments.
Collapse
Affiliation(s)
- Tohru Yorifuji
- Division of Pediatric Endocrinology and Metabolism, Children's Medical Center, Osaka City General Hospital, Osaka, Japan
| | - Reiko Horikawa
- Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan
| | | | - Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Kanagawa, Japan
| | - Shun Soneda
- Department of Pediatrics, St. Marianna University School of Medicine, Kanagawa, Japan
| | | | - Shinobu Ida
- Department of Pediatric Gastroenterology, Nutrition and Endocrinology, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan
| | - Takeo Yonekura
- Department of Pediatric Surgery, Nara Hospital, Kindai University Faculty of Medicine, Nara, Japan
| | - Yoshiaki Kinoshita
- Department of Pediatric Surgery, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Yutaka Kanamori
- Department of Surgery, National Center for Child Health and Development, Tokyo, Japan
| | - Hiroaki Kitagawa
- Division of Pediatric Surgery, St. Marianna University School of Medicine, Kanagawa, Japan
| | - Masato Shinkai
- Department of Surgery, Kanagawa Children's Medical Center, Kanagawa, Japan
| | - Hideyuki Sasaki
- Department of Pediatric Surgery, Tohoku University, Miyagi, Japan
| | - Masaki Nio
- Department of Pediatric Surgery, Tohoku University, Miyagi, Japan
| | | |
Collapse
|
44
|
Adachi M, Oto Y, Muroya K, Hanakawa J, Asakura Y, Goto H. Partial lipodystrophy in patients who have undergone hematopoietic stem cell transplantation during childhood: an institutional cross-sectional survey. Clin Pediatr Endocrinol 2017; 26:99-108. [PMID: 28458462 PMCID: PMC5402311 DOI: 10.1297/cpe.26.99] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/16/2017] [Accepted: 02/20/2017] [Indexed: 12/11/2022] Open
Abstract
Partial lipodystrophy (PD), a condition similar to metabolic syndrome without obesity, is
one of the late complications of hematopoietic stem cell transplantation (HSCT) performed
during childhood. We aimed to investigate the prevalence and risk factors of PD. A
cross-sectional survey was performed in a children’s hospital, targeting patients treated
for a malignancy or hematological disorder, and who were disease-free for > 24 mo. PD
was defined as gluteal lipoatrophy and lipohypertrophy of the cheeks or neck associated
with diabetes and/or fatty liver disease. In total, 65 patients were enrolled. Six
patients (9.2%) were judged to have PD, all of whom had received 10–14 Gy total body
irradiation. Compared with the patients without PD, patients with PD were older at
investigation (P < 0.01), had a longer elapsed time following HSCT (P < 0.01), had
more frequent disease recurrence (P < 0.05), and were more likely to have undergone
multiple HSCT (P < 0.05). In addition, they had higher blood pressure and showed higher
levels of low-density lipoprotein-cholesterol and triglycerides, whereas their adiponectin
levels were significantly lower. In conclusion, a large number of patients developed PD
following HSCT, with unfavorable metabolic profiles at a later age, especially when they
experienced a complex disease course.
Collapse
Affiliation(s)
- Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Yuji Oto
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Koji Muroya
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Junko Hanakawa
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Yumi Asakura
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Hiroaki Goto
- Department of Hematology and Regenerative Medicine, Kanagawa Children's Medical Center, Yokohama, Japan
| |
Collapse
|
45
|
Hinds D, Chapman KR, Piazza P, Gibbs M, Raherison C, Gaalswyk K, Greulich T, Lin J, Adachi M, Davis K. Physician Perspectives on the Burden and Management of Asthma in Six Countries: The Global Asthma Physician Survey (GAPS). Pneumologie 2017. [DOI: 10.1055/s-0037-1598376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- D Hinds
- Worldwide Epidemiology, GlaxoSmithKline, Collegeville, Pennsylvania
| | | | - P Piazza
- Dock Family Medical Practice, Five Dock
| | - M Gibbs
- Global Respiratory Franchise, GlaxoSmithKline, Brentford
| | | | | | | | - J Lin
- China-Japan Friendship Hospital, Beijing
| | - M Adachi
- International University of Health and Welfare, Tokyo
| | - K Davis
- Worldwide Epidemiology, GlaxoSmithKline, Collegeville, Pennsylvania
| |
Collapse
|
46
|
Yamazoe M, Kato T, Suzuki K, Adachi M, Shibayama A, Hoshi K, Itou M, Tsuji N, Sakurai Y, Sakurai H. Spin/orbital and magnetic quantum number selective magnetization measurements for CoFeB/MgO multilayer films. J Phys Condens Matter 2016; 28:436001. [PMID: 27602698 DOI: 10.1088/0953-8984/28/43/436001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Spin selective magnetic hysteresis (SSMH) curves, orbital selective magnetic hysteresis (OSMH) curves and magnetic quantum number selective SSMH curves are obtained for CoFeB/MgO multilayer films by combining magnetic Compton profile measurements and superconducting quantum interference device (SQUID) magnetometer measurements. Although the SQUID magnetometer measurements do not show perpendicular magnetic anisotropy (PMA) in the CoFeB/MgO multilayer film, PMA behavior is observed in the OSMH and SSMH curves for the |m| = 2 magnetic quantum number states. These facts indicate that magnetization switching behavior is dominated by the orbital magnetization of the |m| = 2 magnetic quantum number states.
Collapse
Affiliation(s)
- M Yamazoe
- Department of Electronics and Informatics, Gunma University, 1-5-1 Tenjin-cho, Kiryu, Gunma 376-8515, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Asakura Y, Abe K, Muroya K, Hanakawa J, Oto Y, Narumi S, Hasegawa T, Adachi M. Combined Growth Hormone and Thyroid-Stimulating Hormone Deficiency in a Japanese Patient with a Novel Frameshift Mutation in IGSF1. Horm Res Paediatr 2016; 84:349-54. [PMID: 26302767 DOI: 10.1159/000438672] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2015] [Accepted: 07/10/2015] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Recent reports have indicated that loss-of-function mutations in the immunoglobulin superfamily member 1 gene (IGSF1, OMIM 300888) cause congenital central hypothyroidism with macroorchidism. METHODS We conducted a next-generation sequencing-based comprehensive mutation screening for pituitary hormone deficiencies to elucidate molecular mechanisms other than anatomical abnormalities of the pituitary that might be responsible for multiple anterior hormone deficiency in a male patient who originally visited our institute complaining of short stature. He was born large for gestational age (4,370 g, +3.0 SD) after an obstructed labour. Endocrinological evaluation revealed growth hormone and thyroid-stimulating hormone deficiency. Magnetic resonance imaging showed a discontinuity of the pituitary stalk with an ectopic posterior lobe and a hypoplastic anterior lobe, likely explaining multiple anterior pituitary hormone deficiency. RESULT We identified a novel hemizygous IGSF1 mutation (c.1137_1138delCA, p.Asn380Glnfs*6) in the patient. In reviewing the literature, we noticed that all reported Japanese male IGSF1 mutation carriers were born larger than mean standards for gestational age (mean birth weight SD score of +2.0, 95% confidence interval 1.0-3.0). CONCLUSION This case suggests that more attention should be paid to intrauterine growth and birth history when patients are suspected of having an IGSF1 mutation.
Collapse
Affiliation(s)
- Yumi Asakura
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Sato T, Muroya K, Hanakawa J, Yamashita S, Nozawa K, Masudo K, Yamakawa T, Asakura Y, Hasegawa T, Adachi M. Potential utility of cinacalcet as a treatment for CDC73-related primary hyperparathyroidism: a case report. Clin Pediatr Endocrinol 2016; 25:91-8. [PMID: 27507909 PMCID: PMC4965508 DOI: 10.1297/cpe.25.91] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2015] [Accepted: 03/31/2016] [Indexed: 02/05/2023] Open
Abstract
We report a Japanese pedigree with familial primary hyperparathyroidism due to a CDC73 mutation. To our knowledge, this is the first report of cinacalcet as a treatment for CDC73-related primary hyperparathyroidism. The proband had severe psychomotor retardation and received laryngotracheal separation surgery. At 19 yr of age, he developed acute pancreatitis. Hypercalcemia (12.2-13.8 mg/dL), elevated levels of intact PTH (86-160 pg/mL), and a tumor detected upon neck ultrasonography led to the diagnosis of primary hyperparathyroidism. Family history and biochemical examinations revealed that three family members (the proband's mother, elder brother, and maternal grandfather) had primary hyperparathyroidism. We identified a novel heterozygous mutation, c.240delT, p.Glu81Lysfs*28, in the CDC73 gene in three affected family members, excluding the proband's elder brother who refused genetic testing. Parathyroidectomy for the proband was considered as high-risk, because the tumor was located close to the tracheostomy orifice. After receiving approval from the institutional review board and obtaining the consent, we initiated cinacalcet treatment. At 22 yr of age, treatment with 100 mg of cinacalcet maintained serum calcium levels below 11.0 mg/dL with no apparent side effects. Our report presents the potential efficacy of cinacalcet as a treatment for CDC73-related primary hyperparathyroidism, in particularly inoperative cases.
Collapse
Affiliation(s)
- Takeshi Sato
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan; Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
| | - Koji Muroya
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Junko Hanakawa
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Sumimasa Yamashita
- Department of Child Neurology, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Kumiko Nozawa
- Department of Radiology, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Katsuhiko Masudo
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan
| | - Tadashi Yamakawa
- Department of Endocrinology and Diabetes, Yokohama City University Medical Center, Yokohama, Japan
| | - Yumi Asakura
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| | - Tomonobu Hasegawa
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
| | - Masanori Adachi
- Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
| |
Collapse
|
49
|
Ishii T, Fukuzawa R, Sato T, Muroya K, Adachi M, Ihara K, Igaki J, Hasegawa Y, Sato S, Mitsui T, Hasegawa T. Gonadal macrophage infiltration in congenital lipoid adrenal hyperplasia. Eur J Endocrinol 2016; 175:127-32. [PMID: 27190208 DOI: 10.1530/eje-16-0194] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2016] [Accepted: 05/17/2016] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Congenital lipoid adrenal hyperplasia (lipoid CAH) results in impairment of adrenal and gonadal steroidogenesis caused by STAR mutations. Our previous study revealed upregulation of genes associated with inflammatory or immune response and macrophage infiltration in the adrenal cortex of Star-knockout mice. This study aimed at investigating macrophage infiltration in the gonads from human patients with lipoid CAH. DESIGN This study includes seven patients with lipoid CAH who underwent gonadectomy: two XX women (age, 22 and 40 years) and five XY boys (1 year). Two women with ovarian cysts (32 and 40 years) and six boys with autopsy or tumor (1 year) were examined as controls. Immunohistochemical analysis of their gonads was performed to determine steroidogenic cells by NR5A1 or CYP17A1 and macrophages by IBA1 or CD68. RESULTS An increased number of macrophages infiltrated into the ovaries of lipoid CAH and consisted of two subpopulations: one scattered within and around a layer of theca cells of maturing follicles and the other massively aggregated in the stroma. Abundant cytoplasmic lipid droplets were observed not only in the theca cells but also in the stromal macrophages. There was no significant difference in the number of macrophages in the testicular interstitium between lipoid CAH (95% confidence interval (95% CI: 19.3-47.7 per 0.2mm(2)) and controls (95% CI: 13.3-25.8 per 0.2mm(2)) (P=0.10). CONCLUSIONS These results demonstrate that macrophages infiltrate the ovaries of lipoid CAH, where the theca cells and the stromal macrophages have abundant cytoplasmic lipid droplets.
Collapse
Affiliation(s)
- Tomohiro Ishii
- Department of PediatricsKeio University School of Medicine, Tokyo, Japan
| | - Ryuji Fukuzawa
- Department of Pathology and Laboratory MedicineTokyo Metropolitan Children's Medical Center, Tokyo, Japan
| | - Takeshi Sato
- Department of PediatricsKeio University School of Medicine, Tokyo, Japan Department of Endocrinology and MetabolismKanagawa Children's Medical Center, Yokohama, Japan
| | - Koji Muroya
- Department of Endocrinology and MetabolismKanagawa Children's Medical Center, Yokohama, Japan
| | - Masanori Adachi
- Department of Endocrinology and MetabolismKanagawa Children's Medical Center, Yokohama, Japan
| | - Kenji Ihara
- Department of PediatricsGraduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, and
| | - Junko Igaki
- Department of Endocrinology and MetabolismTokyo Metropolitan Children's Medical Center, Tokyo, Japan
| | - Yukihiro Hasegawa
- Department of Endocrinology and MetabolismTokyo Metropolitan Children's Medical Center, Tokyo, Japan
| | - Seiji Sato
- Department of PediatricsSaitama Municipal Hospital, Saitama, Japan
| | - Toshikatsu Mitsui
- Department of PediatricsKeio University School of Medicine, Tokyo, Japan
| | - Tomonobu Hasegawa
- Department of PediatricsKeio University School of Medicine, Tokyo, Japan
| |
Collapse
|
50
|
Bousquet J, Farrell J, Crooks G, Hellings P, Bel EH, Bewick M, Chavannes NH, de Sousa JC, Cruz AA, Haahtela T, Joos G, Khaltaev N, Malva J, Muraro A, Nogues M, Palkonen S, Pedersen S, Robalo-Cordeiro C, Samolinski B, Strandberg T, Valiulis A, Yorgancioglu A, Zuberbier T, Bedbrook A, Aberer W, Adachi M, Agusti A, Akdis CA, Akdis M, Ankri J, Alonso A, Annesi-Maesano I, Ansotegui IJ, Anto JM, Arnavielhe S, Arshad H, Bai C, Baiardini I, Bachert C, Baigenzhin AK, Barbara C, Bateman ED, Beghé B, Kheder AB, Bennoor KS, Benson M, Bergmann KC, Bieber T, Bindslev-Jensen C, Bjermer L, Blain H, Blasi F, Boner AL, Bonini M, Bonini S, Bosnic-Anticevitch S, Boulet LP, Bourret R, Bousquet PJ, Braido F, Briggs AH, Brightling CE, Brozek J, Buhl R, Burney PG, Bush A, Caballero-Fonseca F, Caimmi D, Calderon MA, Calverley PM, Camargos PAM, Canonica GW, Camuzat T, Carlsen KH, Carr W, Carriazo A, Casale T, Cepeda Sarabia AM, Chatzi L, Chen YZ, Chiron R, Chkhartishvili E, Chuchalin AG, Chung KF, Ciprandi G, Cirule I, Cox L, Costa DJ, Custovic A, Dahl R, Dahlen SE, Darsow U, De Carlo G, De Blay F, Dedeu T, Deleanu D, De Manuel Keenoy E, Demoly P, Denburg JA, Devillier P, Didier A, Dinh-Xuan AT, Djukanovic R, Dokic D, Douagui H, Dray G, Dubakiene R, Durham SR, Dykewicz MS, El-Gamal Y, Emuzyte R, Fabbri LM, Fletcher M, Fiocchi A, Fink Wagner A, Fonseca J, Fokkens WJ, Forastiere F, Frith P, Gaga M, Gamkrelidze A, Garces J, Garcia-Aymerich J, Gemicioğlu B, Gereda JE, González Diaz S, Gotua M, Grisle I, Grouse L, Gutter Z, Guzmán MA, Heaney LG, Hellquist-Dahl B, Henderson D, Hendry A, Heinrich J, Heve D, Horak F, Hourihane JOB, Howarth P, Humbert M, Hyland ME, Illario M, Ivancevich JC, Jardim JR, Jares EJ, Jeandel C, Jenkins C, Johnston SL, Jonquet O, Julge K, Jung KS, Just J, Kaidashev I, Kaitov MR, Kalayci O, Kalyoncu AF, Keil T, Keith PK, Klimek L, Koffi N’Goran B, Kolek V, Koppelman GH, Kowalski ML, Kull I, Kuna P, Kvedariene V, Lambrecht B, Lau S, Larenas-Linnemann D, Laune D, Le LTT, Lieberman P, Lipworth B, Li J, Lodrup Carlsen K, Louis R, MacNee W, Magard Y, Magnan A, Mahboub B, Mair A, Majer I, Makela MJ, Manning P, Mara S, Marshall GD, Masjedi MR, Matignon P, Maurer M, Mavale-Manuel S, Melén E, Melo-Gomes E, Meltzer EO, Menzies-Gow A, Merk H, Michel JP, Miculinic N, Mihaltan F, Milenkovic B, Mohammad GMY, Molimard M, Momas I, Montilla-Santana A, Morais-Almeida M, Morgan M, Mösges R, Mullol J, Nafti S, Namazova-Baranova L, Naclerio R, Neou A, Neffen H, Nekam K, Niggemann B, Ninot G, Nyembue TD, O’Hehir RE, Ohta K, Okamoto Y, Okubo K, Ouedraogo S, Paggiaro P, Pali-Schöll I, Panzner P, Papadopoulos N, Papi A, Park HS, Passalacqua G, Pavord I, Pawankar R, Pengelly R, Pfaar O, Picard R, Pigearias B, Pin I, Plavec D, Poethig D, Pohl W, Popov TA, Portejoie F, Potter P, Postma D, Price D, Rabe KF, Raciborski F, Radier Pontal F, Repka-Ramirez S, Reitamo S, Rennard S, Rodenas F, Roberts J, Roca J, Rodriguez Mañas L, Rolland C, Roman Rodriguez M, Romano A, Rosado-Pinto J, Rosario N, Rosenwasser L, Rottem M, Ryan D, Sanchez-Borges M, Scadding GK, Schunemann HJ, Serrano E, Schmid-Grendelmeier P, Schulz H, Sheikh A, Shields M, Siafakas N, Sibille Y, Similowski T, Simons FER, Sisul JC, Skrindo I, Smit HA, Solé D, Sooronbaev T, Spranger O, Stelmach R, Sterk PJ, Sunyer J, Thijs C, To T, Todo-Bom A, Triggiani M, Valenta R, Valero AL, Valia E, Valovirta E, Van Ganse E, van Hage M, Vandenplas O, Vasankari T, Vellas B, Vestbo J, Vezzani G, Vichyanond P, Viegi G, Vogelmeier C, Vontetsianos T, Wagenmann M, Wallaert B, Walker S, Wang DY, Wahn U, Wickman M, Williams DM, Williams S, Wright J, Yawn BP, Yiallouros PK, Yusuf OM, Zaidi A, Zar HJ, Zernotti ME, Zhang L, Zhong N, Zidarn M, Mercier J. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). Clin Transl Allergy 2016; 6:29. [PMID: 27478588 PMCID: PMC4966705 DOI: 10.1186/s13601-016-0116-9] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2016] [Accepted: 06/02/2016] [Indexed: 01/16/2023] Open
Abstract
Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) focuses on the integrated care of chronic diseases. Area 5 (Care Pathways) was initiated using chronic respiratory diseases as a model. The chronic respiratory disease action plan includes (1) AIRWAYS integrated care pathways (ICPs), (2) the joint initiative between the Reference site MACVIA-LR (Contre les MAladies Chroniques pour un VIeillissement Actif) and ARIA (Allergic Rhinitis and its Impact on Asthma), (3) Commitments for Action to the European Innovation Partnership on Active and Healthy Ageing and the AIRWAYS ICPs network. It is deployed in collaboration with the World Health Organization Global Alliance against Chronic Respiratory Diseases (GARD). The European Innovation Partnership on Active and Healthy Ageing has proposed a 5-step framework for developing an individual scaling up strategy: (1) what to scale up: (1-a) databases of good practices, (1-b) assessment of viability of the scaling up of good practices, (1-c) classification of good practices for local replication and (2) how to scale up: (2-a) facilitating partnerships for scaling up, (2-b) implementation of key success factors and lessons learnt, including emerging technologies for individualised and predictive medicine. This strategy has already been applied to the chronic respiratory disease action plan of the European Innovation Partnership on Active and Healthy Ageing.
Collapse
Affiliation(s)
- J. Bousquet
- CHRU, University Hospital, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
- MACVIA-LR, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc Roussilon, European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France
- INSERM, VIMA: Ageing and Chronic Diseases, Epidemiological and Public Health Approaches, U1168, Paris, France
- UVSQ, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Paris, France
| | - J. Farrell
- Department of Health, Social Services and Public Safety, Belfast, Northern Ireland, UK
| | - G. Crooks
- EIP on AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site, Scottish Centre for Telehealth and Telecare, NHS 24, Glasgow, UK
| | - P. Hellings
- Laboratory of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Louvain, Belgium
- European Academy of Allergy and Clinical Immunology, Zurich, Switzerland
| | - E. H. Bel
- Department of Respiratory Medicine, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands
- European Respiratory Society, Lausanne, Switzerland
| | | | - N. H. Chavannes
- Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands
- Global Alliance Against Chronic Respiratory Diseases (GARD), Cape Town, South Africa
- International Primary Care Respiratory Group, Westhill, UK
| | - J. Correia de Sousa
- Life and Health Sciences Research Institute, ICVS, School of Health Sciences, University of Minho, Braga, Portugal
| | - A. A. Cruz
- Global Alliance Against Chronic Respiratory Diseases (GARD), Cape Town, South Africa
- ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Bahia, Brazil
- GARD Executive Committee, Bahia, Brazil
| | - T. Haahtela
- EIP on AHA Commitment for Action, Lisbon, Portugal
- Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland
| | - G. Joos
- Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
| | - N. Khaltaev
- Global Alliance Against Chronic Respiratory Diseases (GARD), Cape Town, South Africa
| | - J. Malva
- Faculty of Medicine, University of Coimbra, Coimbra, Portugal
- Ageing@Coimbra Reference Site, Coimbra, Portugal
| | - A. Muraro
- European Academy of Allergy and Clinical Immunology, Zurich, Switzerland
- Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy
| | - M. Nogues
- Caisse Assurance Retraite et Santé Au Travail Languedoc-Roussillon (CARSAT-LR), 34000 Montpellier, France
| | - S. Palkonen
- EFA European Federation of Allergy and Airways Diseases Patients’ Associations, Brussels, Belgium
| | - S. Pedersen
- University of Southern Denmark, Kolding, Denmark
| | | | - B. Samolinski
- Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland
| | - T. Strandberg
- Helsinki University, Helsinki University Hospital, Helsinki, Finland
- Center for Life Course Health Research, University of Oulu, Oulu, Finland
- European Union GeriatricMedicine Society, EUGMS, Oslo, Norway
| | - A. Valiulis
- Center of Quality of Life Research, Vilnius University Clinic of Children’s Diseases, Vilnius University Public Health Institute, Vilnius, Lithuania
- European Association of Pediatrics (EAP/UEMS-SP), Brussels, Belgium
| | - A. Yorgancioglu
- Global Alliance Against Chronic Respiratory Diseases (GARD), Cape Town, South Africa
- EIP on AHA Commitment for Action, Lisbon, Portugal
- Department of Pulmonology, Celal Bayar University, Manisa, Turkey
- Turkish Thoracic Society, Antalya, Turkey
| | - T. Zuberbier
- Allergy-Centre-Charité at the Department of Dermatology, Charité - Universitätsmedizin Berlin, Berlin, Germany
- Secretary General of the Global Allergy and Asthma European Network (GA²LEN), Berlin, Germany
| | - A. Bedbrook
- MACVIA-LR, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc Roussilon, European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France
| | - W. Aberer
- Department of Dermatology, Medical University of Graz, Graz, Austria
| | - M. Adachi
- Department of Clinical Research Center, International University of Health and Welfare/Sanno Hospital, Tokyo, Japan
| | - A. Agusti
- Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
- CIBER Enfermedades Respiratorias, Barcelona, Spain
| | - C. A. Akdis
- Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland
| | - M. Akdis
- Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland
| | - J. Ankri
- INSERM, VIMA: Ageing and Chronic Diseases, Epidemiological and Public Health Approaches, U1168, Paris, France
- UVSQ, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Paris, France
| | - A. Alonso
- Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
- CIBER Enfermedades Respiratorias, Barcelona, Spain
| | - I. Annesi-Maesano
- EPAR U707 INSERM, Paris, France
- EPAR UMR-S UPMC, Paris VI, Paris, France
| | - I. J. Ansotegui
- Department of Allergy and Immunology, Hospital Quirón Bizkaia, Erandio, Spain
| | - J. M. Anto
- Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
- Hospital del Mar Research Institute (IMIM), Barcelona, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
- Department of Experimental and Health Sciences, University of Pompeu Fabra (UPF), Barcelona, Spain
| | | | - H. Arshad
- David Hide Asthma and Allergy Research Centre, Isle of Wight, UK
| | - C. Bai
- Shanghai Respiratory Research Institute, Vice President of Respiratory Society, Chinese Medical Association, China and Chinese Alliance Against Lung Cancer, Shanghai, China
| | - I. Baiardini
- Allergy and Respiratory Diseases Clinic, DIMI, IRCCS AOU San Martino-IST, University of Genoa, Genoa, Italy
| | - C. Bachert
- Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium
| | | | - C. Barbara
- Faculdade de Medicina de Lisboa, Portuguese National Programme for Respiratory Diseases (PNDR), Lisbon, Portugal
| | - E. D. Bateman
- Department of Medicine, University of Cape Town, Cape Town, South Africa
| | - B. Beghé
- Section of Respiratory Disease, Department of Oncology, Haematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy
| | - A. Ben Kheder
- Service de pneumologie IV, hôpital Abderrahman Mami, Ariana, 2080 Tunis, Tunisia
| | - K. S. Bennoor
- Department of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh
| | - M. Benson
- Centre for Individualized Medicine, Department of Pediatrics, Faculty of Medicine, LInköping University, Linköping, Sweden
| | - K. C. Bergmann
- Allergy-Centre-Charité at the Department of Dermatology, Charité - Universitätsmedizin Berlin, Berlin, Germany
- Secretary General of the Global Allergy and Asthma European Network (GA²LEN), Berlin, Germany
| | - T. Bieber
- Department of Dermatology and Allergy, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany
| | - C. Bindslev-Jensen
- Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark
| | - L. Bjermer
- Department of Respiratory Medicine and Allergology, University Hospital, Lund, Sweden
| | - H. Blain
- Department of Geriatrics, Montpellier University Hospital, Montpellier, France
- EA 2991, Euromov, University Montpellier, Montpellier, France
| | - F. Blasi
- Department of Pathophysiology and Transplantation, IRCCS Fondazione Ca’Granda Ospedale Maggiore Policlinico, University of Milan, Via F. Sforza 35, Milan, Italy
| | - A. L. Boner
- Pediatric Department, University of Verona Hospital, Verona, Italy
| | - M. Bonini
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy
| | - S. Bonini
- Second University of Naples and Institute of Translational Medicine, Italian National Research Council, Naples, Italy
| | - S. Bosnic-Anticevitch
- Woolcock Institute of Medical Research, University of Sydney and Sydney Local Health District, Glebe, NSW Australia
| | - L. P. Boulet
- Quebec Heart and Lung Institute, Laval University, Québec City, QC Canada
| | - R. Bourret
- Directeur Général Adjoint, Montpellier University Hospital, Montpellier, France
| | | | - F. Braido
- Allergy and Respiratory Diseases Clinic, DIMI, IRCCS AOU San Martino-IST, University of Genoa, Genoa, Italy
| | - A. H. Briggs
- Health Economics and Health Technology Assessment, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
| | - C. E. Brightling
- Respiratory Biomedical Unit, Institute of Lung Health, University Hospitals of Leicester NHS Trust, Leicestershire, UK
- Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK
| | - J. Brozek
- Department of Clinical Epidemiology and Biostatistics, McMaster University, HSC Room 2C16, 1280 Main Street West Hamilton, Hamilton, Canada
| | - R. Buhl
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - P. G. Burney
- National Heart and Lung Institute, Imperial College, London, London, UK
- Wellcome Centre for Global Health, Imperial College, London, London, UK
- MRC-PHE Centre for Environment and Health, Imperial College, London, London, UK
| | - A. Bush
- Imperial College and Royal Brompton Hospital, London, UK
| | | | - D. Caimmi
- Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France
| | - M. A. Calderon
- National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital NHS, London, UK
| | - P. M. Calverley
- Institute of Ageing and Chronic Disease, University of Liverpool and University Hospital Aintree, Liverpool, UK
| | - P. A. M. Camargos
- Department of Pediatrics, Medical School, Federal University of Minas Gerais, Belo Horizonte, Brazil
| | - G. W. Canonica
- Allergy and Respiratory Diseases Clinic, DIMI, IRCCS AOU San Martino-IST, University of Genoa, Genoa, Italy
| | - T. Camuzat
- Région Languedoc Roussillon, Montpellier, France
| | - K. H. Carlsen
- Department of Paediatrics, Oslo University Hospital and University of Oslo, Oslo, Norway
| | - W. Carr
- Allergy and Asthma Associates of Southern California, Mission Viejo, CA USA
| | - A. Carriazo
- Regional Ministry of Equality, Health and Social Policies of Andalusia, Seville, Spain
| | - T. Casale
- Division of Allergy/Immunology, University of South Florida, Tampa, FL USA
| | - A. M. Cepeda Sarabia
- Allergy and Immunology Laboratory, Metropolitan University, Simon Bolivar University, Barranquilla, Colombia
- Asma e Immunologia, SLaai, Sociedad Latinoamericana de Allergia, Barranquilla, Colombia
| | - L. Chatzi
- Department of Social Medicine, Faculty of Medicine, University of Crete, PO Box 2208, Heraklion, 71003 Crete Greece
| | - Y. Z. Chen
- National Cooperative Group of Paediatric Research on Asthma, Asthma Clinic and Education Center of the Capital Institute of Pediatrics, Peking and Center for Asthma Research and Education, Beijing, China
| | - R. Chiron
- Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France
| | - E. Chkhartishvili
- Chachava Clinic, David Tvildiani Medical University-AIETI Medical School, Grigol Robakidze University, Tbilisi, Georgia
| | - A. G. Chuchalin
- GARD Executive Committee, Bahia, Brazil
- Pulmonolory Research Institute FMBA, Moscow, Russia
| | - K. F. Chung
- National Heart and Lung Institute, Imperial College, London, London, UK
| | - G. Ciprandi
- Medicine Department, IRCCS-Azienda Ospedaliera Universitaria San Martino, Genoa, Italy
| | - I. Cirule
- Latvian Allergy Association, Riga, Latvia
| | - L. Cox
- Department of Medicine, Nova Southeastern University, Davie, FL USA
| | - D. J. Costa
- MACVIA-LR, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc Roussilon, European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France
- Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands
| | - A. Custovic
- Department of Paediatrics, Imperial College London, London, UK
| | - R. Dahl
- Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark
| | - S. E. Dahlen
- The Centre for Allergy Research, The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - U. Darsow
- Department of Dermatology and Allergy, Technische Universität München, Munich, Germany
- ZAUM-Center for Allergy and Environment, Helmholtz Center Munich, Technische Universität München, Munich, Germany
| | - G. De Carlo
- EFA European Federation of Allergy and Airways Diseases Patients’ Associations, Brussels, Belgium
| | - F. De Blay
- Allergy Division, Chest Disease Department, University Hospital of Strasbourg, Strasbourg, France
| | - T. Dedeu
- EUREGHA, European Regional and Local Health Association, Brussels, Belgium
- University of Edinburgh, Edinburgh, UK
| | - D. Deleanu
- Allergology and Immunology Discipline, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | | | - P. Demoly
- EPAR U707 INSERM, Paris, France
- Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France
| | - J. A. Denburg
- Department of Medicine, Division of Clinical Immunology and Allergy, McMaster University, Hamilton, ON Canada
| | - P. Devillier
- Laboratoire de Pharmacologie Respiratoire UPRES EA220, Hôpital Foch, Suresnes Université Versailles Saint-Quentin, Suresnes, France
| | - A. Didier
- Respiratory Diseases Department, Rangueil-Larrey Hospital, Toulouse, France
| | - A. T. Dinh-Xuan
- Service de physiologie respiratoire, Hôpital Cochin, Université Paris-Descartes, Assistance publique-Hôpitaux de Paris, Paris, France
| | - R. Djukanovic
- NIHR Southampton Respiratory Biomedical Research Unit, Faculty of Medicine, University Southampton, Southampton, UK
| | - D. Dokic
- Medical Faculty Skopje, University Clinic of Pulmology and Allergy, Skopje, Republic Macedonia
| | - H. Douagui
- Service de Pneumo-Allergologie, Centre Hospitalo-Universitaire de Béni-Messous, Algers, Algeria
| | - G. Dray
- Ecole des Mines, Alès, France
| | - R. Dubakiene
- Medical Faculty, Vilnius University, Vilnius, Lithuania
| | - S. R. Durham
- Allergy and Clinical Immunology Section, National Heart and Lung Institute, Imperial College London, London, UK
| | - M. S. Dykewicz
- Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, MO USA
| | - Y. El-Gamal
- Pediatric Allergy and Immunology Unit, Ain Shams University, Cairo, Egypt
| | - R. Emuzyte
- Clinic of Children’s Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | | | | | - A. Fiocchi
- Division of Allergy, Department of Pediatric Medicine, The Bambino Gesù Children’s Research Hospital Holy See, Rome, Italy
| | - A. Fink Wagner
- Global Allergy and Asthma Platform (GAAPP), Altgasse 8-10, 1130 Vienna, Austria
| | - J. Fonseca
- Center for Health Technology and Services Research - CINTESIS, Faculdade de Medicina, Universidade do Porto, Porto, Portugal
- Allergy Unit, CUF Porto Instituto & Hospital, Porto, Portugal
| | - W. J. Fokkens
- Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, The Netherlands
| | - F. Forastiere
- Department of Epidemiology, Regional Health Service Lazio Region, Rome, Italy
| | - P. Frith
- Repatriation General Hospital, Adelaide, SOUTH AUSTRALIA Australia
| | - M. Gaga
- Athens Chest Hospital, Athens, Greece
| | - A. Gamkrelidze
- National Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia
| | - J. Garces
- Polibienestar Research Institute, University of Valencia, Valencia, Spain
| | - J. Garcia-Aymerich
- Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
- Hospital del Mar Research Institute (IMIM), Barcelona, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
- Department of Experimental and Health Sciences, University of Pompeu Fabra (UPF), Barcelona, Spain
| | - B. Gemicioğlu
- Department of Pulmonary Diseases, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - J. E. Gereda
- Allergy and Immunology Division, Clinica Ricardo Palma, Lima, Peru
| | - S. González Diaz
- Universidad Autónoma de Nuevo León, San Nicolás De La Garza, Mexico
| | - M. Gotua
- Center of Allergy and Immunology, Georgian Association of Allergology and Clinical Immunology, Tbilisi, Georgia
| | - I. Grisle
- Latvian Association of Allergists, Center of Tuberculosis and Lung Diseases, Riga, Latvia
| | - L. Grouse
- Faculty of the Department of Neurology, University of Washington School of Medicine, St. Louis, MO USA
| | - Z. Gutter
- University Hospital Olomouc – National eHealth Centre, Olomouc, Czech Republic
| | - M. A. Guzmán
- Immunology and Allergy Division, Clinical Hospital, University of Chile, Santiago, Chile
| | - L. G. Heaney
- Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, UK
| | - B. Hellquist-Dahl
- Department of Respiratory Diseases, Odense University Hospital, Odense, Denmark
| | - D. Henderson
- EIP on AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site, Scottish Centre for Telehealth and Telecare, NHS 24, Glasgow, UK
| | - A. Hendry
- NHS Scotland, Edinburgh, Scotland, UK
| | - J. Heinrich
- Institute of Epidemiology I, German Research Centre for Environmental Health, Helmholtz Zentrum München, Neuherberg, Germany
| | - D. Heve
- MACVIA-LR, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc Roussilon, European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France
- Agence Régionale de Santé, 34067 Montpellier Cedex 2, France
| | - F. Horak
- Vienna Challenge Chamber, Vienna, Austria
| | - J. O’. B. Hourihane
- Department of Paediatrics and Child Health, University College Cork, Cork, Ireland
| | - P. Howarth
- University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton, UK
| | - M. Humbert
- Service de Pneumologie, Hôpital Bicêtre, Inserm UMR_S999, Université Paris-Sud, Le Kremlin Bicêtre, France
| | - M. E. Hyland
- School of Psychology, Plymouth University, Plymouth, UK
| | - M. Illario
- Federico II University Hospital/Campania RS, Naples, Italy
| | - J. C. Ivancevich
- Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina
| | - J. R. Jardim
- Universidade Federal de Sao Paulo, São Paulo, Brazil
| | | | - C. Jeandel
- MACVIA-LR, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc Roussilon, European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France
- Department of Geriatrics, Montpellier University Hospital, Montpellier, France
| | - C. Jenkins
- The George Institute for Global Health, The University of Sydney, Camperdown, Australia
| | - S. L. Johnston
- Airway Disease Infection Section, National Heart and Lung Institute, Imperial College, London, London, UK
- MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK
| | - O. Jonquet
- Medical Commission, Montpellier University Hospital, Montpellier, France
| | - K. Julge
- Children’s Clinic of Tartu University Hospital, Tartu, Estonia
| | - K. S. Jung
- Hallym University College of Medicine, Hallym University Sacred Heart Hospital, Gyeonggi-Do, South Korea
| | - J. Just
- Allergology Department, Centre de l’Asthme et des Allergies, Hôpital d’Enfants Armand-Trousseau (APHP), Paris, France
- Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Equipe EPAR, 75013 Paris, France
| | - I. Kaidashev
- Ukrainian Medical Stomatological Academy, Poltava, Ukraine
| | - M. R. Kaitov
- Federal Medicobiological Agency, Laboratory of Molecular Immunology, Institute of Immunology, National Research Center, Moscow, Russian Federation
| | - O. Kalayci
- Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey
| | - A. F. Kalyoncu
- Immunology and Allergy Division, Department of Chest Diseases, School of Medicine, Hacettepe University, Ankara, Turkey
| | - T. Keil
- Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany
- Institute for Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany
| | - P. K. Keith
- Department of Medicine, McMaster University, Health Sciences Centre 3V47, 1280 Main Street West, Hamilton, Canada
| | - L. Klimek
- Center for Rhinology and Allergology, Wiesbaden, Germany
| | - B. Koffi N’Goran
- Société de Pneumologie de Langue Française, Espace francophone de Pneumologie, Paris, France
| | - V. Kolek
- Department of Respiratory Medicine, Faculty of Medicine and Dentistry, University Hospital Olomouc, Olomouc, Czech Republic
| | - G. H. Koppelman
- GRIACResearch Institute, Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children’s Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - M. L. Kowalski
- Department of Immunology, Rheumatology and Allergy, Medical University of Lodz, and HARC, Lodz, Poland
| | - I. Kull
- Sachs’ Children’s Hospital, Stockholm, Sweden
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - P. Kuna
- Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland
| | - V. Kvedariene
- Clinic of Infectious, Chest Diseases, Dermatology and Allergology, Vilnius University, Vilnius, Lithuania
| | - B. Lambrecht
- VIB Inflammation Research Center, Ghent University, Ghent, Belgium
| | - S. Lau
- Department for Pediatric Pneumology and Immunology, Charité Medical University, Berlin, Germany
| | - D. Larenas-Linnemann
- Clínica de Alergia, Asma y Pediatría, Hospital Médica Sur, Ciudad De México, Mexico
| | - D. Laune
- Digi Health, Montpellier, France
| | - L. T. T. Le
- University of Medicine and Pharmacy, Hochiminh City, Vietnam
| | - P. Lieberman
- Divisions of Allergy and Immunology, Departments of Internal Medicine and Pediatrics, University of Tennessee College of Medicine, Germantown, TN USA
| | - B. Lipworth
- Scottish Centre for Respiratory Research, Cardiovascular and Diabetes Medicine, Medical Research Institute, Ninewells Hospital, University of Dundee, Dundee, UK
| | - J. Li
- State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120 China
| | - K. Lodrup Carlsen
- Department of Paediatrics, Oslo University Hospital, Oslo, Norway
- Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - R. Louis
- Department of Pulmonary Medicine, CHU Sart-Tilman, Liege, Belgium
| | - W. MacNee
- Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK
| | - Y. Magard
- Service de Pneumo-allergologie, Hôpital Saint-Joseph, Paris, France
| | - A. Magnan
- Service de Pneumologie, UMR INSERM, UMR1087and CNR 6291, l’institut du thorax, University of Nantes, Nantes, France
| | - B. Mahboub
- Department of Pulmonary Medicine, Rashid Hospital, Dubai, UAE
| | - A. Mair
- Scottish Government Health Department, eHealth and Pharmaceuticals, Edinburgh, UK
| | - I. Majer
- Department of Respiratory Medicine, University of Bratislava, Bratislava, Slovakia
| | - M. J. Makela
- Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland
| | - P. Manning
- Department of Medicine (RCSI), Bon Secours Hospital, Glasnevin, Dublin, Ireland
| | - S. Mara
- Cardiovascular and Thoracic Department, AOU Città della Salute e della Scienza di Torino, Turin, Italy
| | - G. D. Marshall
- Division of Clinical Immunology and Allergy, Laboratory of Behavioral Immunology Research, The University of Mississippi Medical Center, Jackson, MS USA
| | - M. R. Masjedi
- Respiratory Medicine Research, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | | | - M. Maurer
- Allergie-Centrum-Charité at the Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - S. Mavale-Manuel
- Department of Paediatrics, Maputo Central Hospital, Maputo, Mozambique
| | - E. Melén
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - E. Melo-Gomes
- PNDR/Portuguese National Programme for Respiratory Diseases, Lisbon, Portugal
| | - E. O. Meltzer
- Allergy and Asthma Medical Group and Research Center, San Diego, CA USA
| | | | - H. Merk
- Hautklinik - Klinik für Dermatologie & Allergologie, Universitätsklinikum der RWTH Aachen, Aachen, Germany
| | - J. P. Michel
- European Union GeriatricMedicine Society, EUGMS, Oslo, Norway
| | | | - F. Mihaltan
- National Institute of Pneumology M. Nasta, Bucharest, Romania
| | - B. Milenkovic
- Faculty of Medicine, University of Belgrade, Belgrade, Serbia
- Serbian Association for Asthma and COPD, Belgrade, Serbia
| | - G. M. Y. Mohammad
- National Center for Research in Chronic Respiratory Diseases, Tishreen University School of Medicine, Latakia, Syria
| | - M. Molimard
- Département de Pharmacologie, CHU de Bordeaux, Universite Bordeaux, INSERM U657, Bordeaux Cedex, France
| | - I. Momas
- Department of Public Health and Biostatistics, EA 4064, Paris Descartes University, Paris, France
- Paris Municipal Department of Social Action, Childhood, and Health, Paris, France
| | | | - M. Morais-Almeida
- Allergy and Clinical Immunology Department, Hospital CUF-Descobertas, Lisbon, Portugal
| | - M. Morgan
- National Clinical Director for Respiratory Services, NHS England, Leeds, England, UK
| | - R. Mösges
- Institute of Medical Statistics, Informatics and Epidemiology, Medical Faculty, University of Cologne, Cologne, Germany
| | - J. Mullol
- Sachs’ Children’s Hospital, Stockholm, Sweden
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
- Unitat de Rinologia i Clínica de l’Olfacte, Servei d’ORL, Hospital Clínic, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain
| | - S. Nafti
- Mustapha Hospital, Algers, Algeria
| | - L. Namazova-Baranova
- Scientific Centre of Children’s Health Under the Russian Academy of Medical Sciences, Moscow, Russia
| | - R. Naclerio
- Section of Otolaryngology-Head and Neck Surgery, The University of Chicago Medical Center and The Pritzker School of Medicine, The University of Chicago, Chicago, IL USA
| | - A. Neou
- Allergy-Centre-Charité at the Department of Dermatology, Charité - Universitätsmedizin Berlin, Berlin, Germany
- Secretary General of the Global Allergy and Asthma European Network (GA²LEN), Berlin, Germany
| | - H. Neffen
- Hospital de Niños Orlando Alassia, Santa Fe, Argentina
| | - K. Nekam
- Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary
| | - B. Niggemann
- Pediatric Pneumology and Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - G. Ninot
- EA4556 Epsylon, Université Montpellier 1, Montpellier, France
| | - T. D. Nyembue
- ENT Department, University Hospital of Kinshasa, Kinshasa, Congo
| | - R. E. O’Hehir
- Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC Australia
- Department of Immunology, Monash University, Melbourne, VIC Australia
| | - K. Ohta
- National Hospital Organization, Tokyo National Hospital, Tokyo, Japan
| | - Y. Okamoto
- Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan
| | - K. Okubo
- Department of Otolaryngology, Nippon Medical School, Tokyo, Japan
| | - S. Ouedraogo
- Centre Hospitalier Universitaire Pédiatrique Charles de Gaulle, Ouagadougou, Burkina Faso
| | - P. Paggiaro
- Cardio-Thoracic and Vascular Department, University Hospital of Pisa, Pisa, Italy
| | - I. Pali-Schöll
- Department of Comparative Medicine, Messerli, Research Institute of the University of Veterinary Medicine and Medical University, Vienna, Austria
| | - P. Panzner
- Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic
| | - N. Papadopoulos
- Center for Pediatrics and Child Health, Institute of Human Development, Royal Manchester Children’s Hospital, University of Manchester, Manchester, M13 9WL UK
- Allergy Department, 2nd Pediatric Clinic, Athens General Children’s Hospital “P&A Kyriakou”, University of Athens, Athens, 11527 Greece
| | - A. Papi
- Respiratory Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
| | - H. S. Park
- Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea
| | - G. Passalacqua
- Allergy and Respiratory Diseases Clinic, DIMI, IRCCS AOU San Martino-IST, University of Genoa, Genoa, Italy
| | - I. Pavord
- Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - R. Pawankar
- Department of Pediatrics, Nippon Medical School, Tokyo, Japan
| | - R. Pengelly
- Department of Health, Social Services and Public Safety, Belfast, Northern Ireland, UK
| | - O. Pfaar
- Center for Rhinology and Allergology, Wiesbaden, Germany
- Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - R. Picard
- Conseil Général de l’Economie. Ministère de l’Economie, de l’Industrie et du Numérique, Paris, France
| | - B. Pigearias
- Société de Pneumologie de Langue Française, Espace francophone de Pneumologie, Paris, France
| | - I. Pin
- Département de pédiatrie, CHU de Grenoble, BP 217, 38043 Grenoble Cedex 9, France
| | - D. Plavec
- Children’s Hospital Srebrnjak, Zagreb, School of Medicine, University J.J. Strossmayer, Osijek, Croatia
| | - D. Poethig
- Im GerontoLab Europe - Europäische Vereinigung für Vitalität und Aktives Altern (eVAA) e.V., Leipzig, Germany
| | - W. Pohl
- Karl Landsteiner Institute for Clinical and Experimental Pneumology, Hietzing Hospital, Wolkersbergenstraße 1, 1130 Vienna, Austria
| | - T. A. Popov
- Clinic of Allergy and Asthma, Medical University Sofia, 1Sv. Georgi Sofiyski St., 1431 Sofia, Bulgaria
| | - F. Portejoie
- MACVIA-LR, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc Roussilon, European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France
| | - P. Potter
- Allergy Diagnostic and Clinical Research Unit, University of Cape Town Lung Institute, Cape Town, South Africa
| | - D. Postma
- Department of Pulmonary Medicine and Tuberculosis, GRIAC Research Institute, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - D. Price
- Academic Centre of Primary Care, University of Aberdeen, Aberdeen, UK
- Research in Real-Life, Cambridge, UK
| | - K. F. Rabe
- LungenClinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany
- Department of Medicine, Christian Albrechts University, Airway Research Center North, Member of the German Center for Lung Research (DZL), Kiel, Germany
| | - F. Raciborski
- Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland
| | - F. Radier Pontal
- Conseil Départemental de l’Ordre des Pharmaciens, Maison des Professions Libérales, 34000 Montpellier, France
| | | | - S. Reitamo
- Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland
| | - S. Rennard
- Division of Pulmonary, Critical Care, Sleep and Allergy, University of Nebraska Medical Center, Omaha, NE USA
| | - F. Rodenas
- Polibienestar Research Institute, University of Valencia, Valencia, Spain
| | - J. Roberts
- Salford, Royal NHS Foundation Trust and NHS England North, London, UK
| | - J. Roca
- Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
| | - L. Rodriguez Mañas
- Hospital Universitario de Getafe-Servicio Madrileño de Salud, Madrid, Spain
| | - C. Rolland
- Association Asthme et Allergie, Paris, France
| | - M. Roman Rodriguez
- Primary Care Respiratory Research Unit, Institutode Investigación Sanitaria de Palma IdisPa, Palma De Mallorca, Spain
| | - A. Romano
- Allergy Unit, Complesso integrato Columbus, Rome, Italy
| | - J. Rosado-Pinto
- Serviço de Imunoalergologia, Hospital da Luz, Lisbon, Portugal
| | - N. Rosario
- Hospital de Clinicas, University of Parana, Curitiba, PR Brazil
| | - L. Rosenwasser
- Department of Allergy, Asthma, and Immunology, Children’s Mercy Hospitals and Clinics and Pediatrics, Medicine University of Misouri-Kansas City School of Medicine, Kansas City, MO USA
| | - M. Rottem
- Division of Allergy Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel
| | - D. Ryan
- Woodbrook Medical Centre, Loughborough, UK
- Honorary Clinical Research Fellow, Allergy and Respiratory Research Group, The University of Edinburgh, Edinburgh, UK
| | - M. Sanchez-Borges
- Allergy and Clinical Immunology Department, Centro Médico-Docente la, Trinidad and Clínica El Avila, 6a transversal Urb, Altamira, piso 8, consultorio 803, Caracas, 1060 Venezuela
| | - G. K. Scadding
- The Royal National TNE Hospital, University College London, London, UK
| | - H. J. Schunemann
- Department of Clinical Epidemiology and Biostatistics, McMaster University, HSC Room 2C16, 1280 Main Street West Hamilton, Hamilton, Canada
| | - E. Serrano
- Otolaryngology and Head and Neck Surgery, CHU Rangueil-Larrey, Toulouse, France
| | - P. Schmid-Grendelmeier
- Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
| | - H. Schulz
- Helmholtz Zentrum München/Institute of Epidemiology I, Neuherberg, Germany
| | - A. Sheikh
- Allergy and Respiratory Research Group, Centre for Population Health Sciences, Medical School, The University of Edinburgh, Edinburgh, UK
| | - M. Shields
- Child Health, Queen’s University Belfast and Royal Belfast Hospital for Sick Children, Belfast, UK
| | - N. Siafakas
- Department of Thoracic Medicine, University Hospital of Heraklion, Crete, Greece
| | - Y. Sibille
- University Hospital of Mont-Godinne, Catholic University of Louvain, Yvoir, Belgium
| | - T. Similowski
- Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France
- INSERM, UMR_S 1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France
- Department R3S, AP-HP, Groupe, Paris, France
| | - F. E. R. Simons
- Department of Pediatrics and Child Health, Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, MB Canada
| | - J. C. Sisul
- Sociedad Paraguaya de Alergia Asma e Inmunología, Asunción, Paraguay
| | - I. Skrindo
- Department of Paediatrics, Oslo University Hospital, Oslo, Norway
- Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - H. A. Smit
- Julius Center of Health Sciences and Primary Care, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands
| | - D. Solé
- Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of São Paulo, São Paulo, Brazil
| | - T. Sooronbaev
- Kyrgyzstan National Centre of Cardiology and Internal Medicine, Euro-Asian Respiratory Society, Bishkek, Kyrgyzstan
| | - O. Spranger
- Global Allergy and Asthma Platform (GAAPP), Altgasse 8-10, 1130 Vienna, Austria
| | - R. Stelmach
- Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Brazil
| | - P. J. Sterk
- Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
| | - J. Sunyer
- Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
- Hospital del Mar Research Institute (IMIM), Barcelona, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
- Department of Experimental and Health Sciences, University of Pompeu Fabra (UPF), Barcelona, Spain
| | - C. Thijs
- Department of Epidemiology, CAPHRI School of Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands
| | - T. To
- Sidkkids hospitala and Institute of Health Policy, Management and Evaluation, Toronto, ON Canada
| | - A. Todo-Bom
- Centre of Pneumology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
| | - M. Triggiani
- Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy
| | - R. Valenta
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - A. L. Valero
- Pneumology and Allergy Department, Hospital Clínic, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain
| | - E. Valia
- Polibienestar Research Institute, University of Valencia, Valencia, Spain
| | - E. Valovirta
- Department of Lung Diseases and Clinical Allergology, University of Turku, Turku, Finland
| | - E. Van Ganse
- Unité de Pharmacoépidémiologie, CHU-Lyon - UR 5558 CNRS, Université Claude Bernard, Lyon, Villeurbanne, France
| | - M. van Hage
- Clinical Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet and University Hospital, Stockholm, Sweden
| | - O. Vandenplas
- Department of Chest Medicine, Centre Hospitalier Universitaire Dinant-Godinne, Université Catholique de Louvain, Yvoir, Belgium
| | - T. Vasankari
- FILHA, Finnish Lung Association, Helsinki, Finland
| | - B. Vellas
- Gérontopôle, CHU Toulouse, Toulouse, France
| | - J. Vestbo
- Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK
- University Hospital of South Manchester, Manchester NHS Foundation Trust, Manchester, UK
| | - G. Vezzani
- Pulmonary Unit, Department of Cardiology, Thoracic and Vascular Medicine, Arcispedale S.Maria Nuova/IRCCS, Research Hospital, Reggio Emilia, Italy
- Regional Agency for Health and Social Care, Reggio Emilia, Italy
| | - P. Vichyanond
- Division of Allergy and Immunology, Department of Pediatrics, Siriraj Hospital, Mahidol University Faculty of Medicine, Bangkok, 10700 Thailand
| | - G. Viegi
- Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Pisa, Via Trieste 41, 56126 Pisa, Italy
- CNR Institute of Biomedicine and Molecular Immunology “A. Monroy”, Via U. La Malfa 153, 90146 Palermo, Italy
| | - C. Vogelmeier
- Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Marburg, Germany
| | | | - M. Wagenmann
- Department of Otorhinolaryngology, HNO-Klinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany
| | - B. Wallaert
- Hôpital Albert Calmette, CHRU, Lille, France
| | - S. Walker
- Asthma UK, Mansell Street, London, UK
| | - D. Y. Wang
- Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
| | - U. Wahn
- Pediatric Pneumology and Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - M. Wickman
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - D. M. Williams
- Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC USA
| | - S. Williams
- International Primary Care Respiratory Group, Westhill, UK
| | - J. Wright
- Bradford Institute for Health Research, Bradford Royal Infirmary, Bradford, UK
| | - B. P. Yawn
- Department of Research, Olmsted Medical Center, Rochester, MN USA
| | - P. K. Yiallouros
- Cyprus International Institute for Environmental and Public Health in Association with Harvard School of Public Health, Cyprus University of Technology, Limassol, Cyprus
- Department of Pediatrics, Hospital “Archbishop Makarios III”, Nicosia, Cyprus
| | - O. M. Yusuf
- The Allergy and Asthma Institute, Lahore, Pakistan
| | - A. Zaidi
- Social Sciences, University of Southampton, Southampton, UK
| | - H. J. Zar
- Department of Paediatrics and Child Health, Red Cross Children’s Hospital, and MRC Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
| | | | - L. Zhang
- Department of Otolaryngology, Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730 China
| | - N. Zhong
- State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120 China
| | - M. Zidarn
- University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia
| | - J. Mercier
- Department of Physiology, CHRU and Vice President for Research, University Montpellier, Montpellier, France
| |
Collapse
|